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Increased advanced glycation endproducts (AGEs) formation and oxidative stress are 
believed to underlie the pathogenesis of diabetic vascular complications including the 
impairment of the wound healing. In most developing countries, diabetic treatment is 
expensive and plants provide a cheap potential natural source of anti-diabetic remedies. 
Several studies have examined the beneficial effects of using Momordica charantia (MC) 
because of its hypoglycaemic properties in diabetic subjects. Here, for the first time, the anti-
glycation and antioxidant properties of aqueous extracts of Momordica charantia pulp 
(MCP), flesh (MCF) and charantin were assessed in vitro. Since wound-healing is one of the 
most costly complications and affecting 15% of diabetic patients, the potential angiogenic 
activities of MCP, MCF and charantin in the presence or absence of AGEs were investigated.  
Lysozyme was glycated using either glucose or methylglyoxal in the presence or absence of 5 
to 15 mg/ml of Momordica charantia extracts in 0.1 M sodium phosphate buffer (pH 7.4) at 
37°C for three days. The formation of  glucose or methylglyoxal-derived AGE crosslinks was 
assessed using sodium dodecyl sulphate-polyacrylamide gel electrophoresis followed by 
Coomassie blue staining. A non-competitive ELISA method was used to investigate the 
effect of Momordica charantia extracts on carboxymethyllysine (CML) concentrations. 
Antioxidant activities of all extracts of Momordica charantia were evaluated using the stable 
free radical 1,1-diphenyl-2-picrylhydrazyl (DPPH) and hydroxyl radical-scavenging activity, 
metal chelating activity and reducing power. The phenolic, flavonols and flavonoid contents 
of all extracts were also measured. In vitro angiogenic assays including cell proliferation, 
migration and endothelial tube formation in Matrigel™ were used to assess the potential 
angiogenic effects of the natural extracts. By Western blotting, the angiogenic signalling 
pathways induced by AGEs and potentially modulated by MCP, MCF and charantin were 
also investigated. Furthermore, the neutralization of the receptor for AGEs (RAGE) was 
xii 
 
performed using a monoclonal anti-RAGE antibody to highlight the role of RAGE in the 
modulation of AGE-induced signalling pathways followed addition of MCP, MCF and 
charantin.  
All extracts inhibited the formation of MG-derived AGEs in a dose-dependent manner and 
the MCF extract showed the most potent inhibitory effect on both AGE and CML formation. 
Antioxidant capacity of MCF was significantly higher than MCP based upon the DPPH and 
hydroxyl radical-scavenging activity (p < 0.005); however, MCP shows higher metal-
chelating activity in comparison to other extracts. The content of phenolic compounds was 
expressed in gallic acid equivalents (GAE), whereas flavonols and flavonoid contents were 
expressed in rutin equivalents (RE). In addition, all Momordica charantia extracts increased 
bovine aortic endothelial cell (BAEC) proliferation, migration and tube formation with 
induction of p-ERK1/2 expression through RAGE. Moreover, these natural extracts 
decreased the anti-angiogenic effects of high concentration of BSA-AGEs.  
Momordica charantia does not only have established hypoglycaemic effects but this study 
shows that crude extracts are capable of preventing MG-derived cross-linked AGEs and 
Glyoxalic acid-derived CML at least in vitro. This anti-glycation activity might be due to 
their antioxidant properties from their phenolic content. Furthermore, because of its pro-
angiogenic effects and its ability to reduce the AGEs-induced anti-angiogenic effect, 
Momordica charantia presents a promising natural product for the development of a new 
strategy to accelerate wound-healing especially in diabetic foot. Thus, use of Momordica 
charantia deserves more attention in particular its ability to reduce AGE formation and 
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Chapter 1. Introduction 
1.1 Diabetes Mellitus 
Diabetes mellitus (DM) is a metabolic multiple aetiology disease associated with high blood 
sugar concentration. When untreated, it may lead to a number of medical complications 
including chronic hyperglycaemia and disturbances in the metabolism of proteins, fats and 
carbohydrates (Al-Hassan, 2003; Patel et al, 2012). The elevated blood sugar of a patient 
suffering from diabetes mellitus occurs due to the pancreas’ failure to produce adequate 
levels of insulin. In addition, it also can occur because the patient’s cells prove unresponsive 
to any insulin produced. It is consequently possible to observe abnormal insulin synthesis and 
incorrect manifestation of its properties during onset of the disease (ADA, 2009).  
DM has become increasingly prevalent in recent years. The massive incidence of DM in the 
world is believed to have been a result of several factors, such as increased consumption of 
calorie-rich diets, increases in the ageing population, lifestyles and obesity (ADA, 2014; 
Romao and Roth, 2008). As a very common chronic disease, DM was considered the fifth 
leading cause of death (Malik, 2014). DM caused 1.5 million (2.7%) deaths in 2012, up from 
1.0 million (2.0%) deaths in 2000. International Diabetes Federation (IDF) has predicted that 
the worldwide number of patients with diabetes will increase by the year 2035 to 592 million, 
with figures for 2013 standing at approximately 382 million (IDF, 2013).  
DM is divided into three types. Type 1 diabetes, also known as insulin-dependent diabetes 
mellitus (IDDM) (ADA, 2010), is observed when the body fails to generate insulin. In 
particular, insulin deficiency is detected when the pancreas loses insulin-generating beta cells 
located in the islets of Langerhans. In this case, the patient is required to wear a specialised 
insulin pump or inject insulin on a daily basis. In contrast, type 2 diabetes is diagnosed 
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because of insulin resistance. It is most commonly observed in adults and is therefore often 
known as ‘adult-onset diabetes’. This condition is characterised by the cells’ inability to 
interact efficiently with insulin. In certain cases, type 2 diabetes is observed in conjunction 
with absolute insulin deficiency. This type of diabetes is known as non-insulin-dependent 
diabetes mellitus (NIDDM). However, a decision was made to abolish the NIDDM and 
IDDM acronyms because of their confusing natures. Thus, diabetic patients are now 
classified according to the observed pathogenesis of their diseases rather than according to 
their treatment (ADA, 2010). The third type of diabetes is known as gestational 
hyperglycaemia. This condition is described as a patient’s intolerance towards carbohydrates 
during pregnancy even if the patient has a pre-existing diabetic condition (Nakata et al, 
2013). Hyperglycaemia is a common condition during diabetes mellitus. It is associated with 
a range of diabetic complications. 
1.2 Hyperglycaemia and diabetic complications 
The biomedical field defines hyperglycaemia as a condition during which an elevated 
quantity of sugar is present in the blood. According to ADA diagnosis criteria, fasting plasma 
glucose (FPG) ≥ 7 mmol/l and HbA1c ≥ 6.5 % can be diagnosed as diabetic (ADA, 2013). 
However, initial hyperglycaemic symptoms are observed at concentrations ranging from 15–
20 mmol/l (Cox et al., 2005).  
Diabetic complications can be either microvascular or macrovascular. Microvascular 
complications refer to a range of pathological functional changes that take place at the 
microvascular level. Increased blood sugar levels lead to microvascular damage and 
conditions such as retinopathy, neuropathy, nephropathy and cardiomyopathy (Nathan et al., 
2005). Microvascular complications develop within 10–15 years in diabetic patients. They 
are typical chronic complications associated with lowered life expectancy and considerable 
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morbidity (Ali et al., 2010). In the context of diabetes, the notion of macrovascular 
complications was conceived to describe a range of pathological changes taking place in all 
main blood vessels resulting in structural and functional alterations. Chronic hyperglycaemia 
leads to chemical changes occurring in the inner walls of blood vessels. These changes result 
in endothelial dysfunctions, increased arterial wall stiffness and lowered compliance of the 
vascular system, thus promoting macrovascular complications. A common macrovascular 
complication is atherosclerosis. It is believed to be responsible for the elevated risk of stroke, 
peripheral vascular pathologies and myocardial infarction (Laakso, 2010).  
1.3 Protein glycation (Maillard reaction) 
Glycation is the addition of sugars, such as fructose or glucose, to lipids or proteins. This 
non-enzymatic reaction, which takes place between protein amino groups and reduces sugars, 
leads to the formation of complex, brown-coloured pigments as well as protein-protein 
covalent bonds. Glycation was discovered and investigated by Louis Maillard (1912). 
Compared to other reducing sugars, glucose is the least reactive; thus, it was speculated that 
glucose was chosen during evolution as the main free sugar present in vivo. Nevertheless, 
similar to other carbohydrates, it reacts with free amino acid lysine ε-amino and arginine 
groups, which leads to the formation of a Schiff base. As shown in Figure 1, a C=O aldehyde 
group is converted into an imine C=N group during the formation of this base (Ulrich and 
Cerami, 2001). 
Maillard indicated that the reaction he discovered could potentially play a vital role in 
diabetes, but this idea was too radical for his time. The technology available in the early 
1900s made it impossible to support or reject this presumption. However, the practical 
significance of the process was soon realised by food chemists, as they were able to explain 
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the brown colour and the loss of certain protein properties during cooking or food storage 
(Ulrich and Cerami, 2001). 
The Maillard reaction’s clinical significance was realised in the mid-1970s. Initial 
investigations were concerned with the reaction between sugars and haemoglobin A1c 
(HbA1c). This form of haemoglobin is minor, but its quantity in blood is elevated exclusively 
in diabetics. Additionally, HbA1c formed via the addition of glucose molecules to amino 
groups located on haemoglobin β-chains. This reaction was believed to proceed via a non-
enzymatically obtained Schiff structure. The fact that Schiff bases were usually 
thermodynamically unstable presented a major argument against this assumption. Further 
investigations showed that Schiff bases were only intermediate structures and led to an 
Amadori rearrangement. The final product, a carbohydrate fragment, is attached to the HbA1c 
molecule as a 1-deoxy-1-fructosyl fragment (Figure 1.1) (Ulrich and Cerami, 2001). 
It was suggested that the Maillard reaction was important in the pathogenesis of diabetic 
complications and the promotion of aging (Brownlee, 1992). Subsequently, proteins 
containing Amadori products in the main polypeptide chain were called glycated proteins. 
The term was coined to distinguish them from glycosylated proteins, which were obtained 
with the aid of enzymes. In turn, the process during which Amadori products form was called 
glycation. Cross-links and complex pigments formed during the course of the Maillard 
reaction from glycated proteins were referred to as advanced glycation end-products (AGE) 




Figure 1.1: Formation of a Schiff base and subsequent Amadori rearrangement (Ulrich 
and Cerami, 2001) 
 
1.4 Chemistry of protein glycation 
1.4.1 Protein glycation: early stage  
The kinetics of the early stage depend extensively on water activity, media temperature 
(Davies et al., 1998; Wang et al., 2013), the carbonyl carbon electrophilicity and the quantity 
of sugar present in blood in the acyclic form (Yaylayan et al., 1994). It was also suggested 
that the pKa of protein, the amino groups and their location within the molecule influences 
protein glycation’s early stage (Spiro, 2002). Early stage protein glycation is represented in 
Figure 1.1. 
1.4.2 Protein glycation: intermediate stage 
The intermediate stage of protein glycation begins with deoxyosone degradation via 
dehydration of the Heyns and Amadori products. The primary deoxyosones are identified and 






Figure 1.2: Deoxyosones obtained from Amadori products (Dills, 1993) 
 
Formation of the deoxyosones (Figure 1.2) is considered to proceed via 2, 3 or 1, 2-
enolisation of the sugar residue under acidic conditions (Yaylayan et al., 1994). The 
deoxyosones’ chemistry presumes an array of possible transformations taking place with the 
amino-carbonyl group (Figure 1.3). The initial enolisation leads to the formation of 




Figure 1.3: Formation of 1-amino-1,4-dideoxyosones from deoxyosones (Dills, 1993). 
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1.4.3 Protein glycation: advanced stage 
The advanced stage of protein glycation is characterised by the formation of AGEs. AGEs 
present a heterogeneous group of organic molecules obtained from the protein glycation 
products formed during the intermediate stages of glycation. For instance, deoxyosones can 
undergo intra- and inter-molecular transformations leading to the formation of pyrraline and 
pentosidine (Figure 1.4) (Dills, 1993). AGEs can be fluorescent or non-fluorescent and cross-




Figure 1.4: Pyrraline and pentosidine (Dills, 1993) 
1.5 Glycation and oxidation reaction (other pathways for AGE formation) 
1.5.1 Autoxidative glycation (Wolf pathway) 
The autoxidation of monosaccharides is a non-enzymatic reaction between the α-
hydroxycarbonyl group of sugar and oxygen. The main products of the process are α-
oxoaldehydes and hydrogen peroxide. This reaction was discovered by Wolf and co-workers 
in 1984 (Wolff and Dean, 1987). It was suggested that free radicals play a key role in this 
process and the reaction was started by the enolisation of the initial monosaccharide. 
Subsequently, the formed enediol was dehydrated to a dicarbonyl compound. These reactions 





Figure 1.5: Autoxidative glycation (Wolf pathway) 
  
Along with dicarbonylic compounds, glucosone and a range of additional AGE products are 
formed. Thus, the glucose molecules lose either erythrose or erythritol to give glyoxal and 3-
deoxyglucosone, which react with the production of glyceraldehyde and methylglyoxal 
(Monnier, 2003). 
1.5.2 Schiff base fragmentation (Namiki pathway) 
In certain cases, the Schiff base does not enter the Amadori rearrangement but undergoes a 
series of elimination reactions leading to the production of AGEs. These elimination 
reactions lead to the release of a primary amine and a range of unstable dialdehydes, such as 
methylglyoxal, glucosone and glyoxal (Ferreira et al., 2003). These products and the 
corresponding reaction pathway were initially described by Namiki and Hayashi (1983) 





Figure 1.6: The Namiki pathway of AGE formation (Baynes, 2001) 
 
1.5.3 Glycoxidation reactions 
The term ‘glycoxidation products’ was originally introduced in order to characterise products 
formed by sequential glycation and oxidation reactions; however, it is commonly utilised to 
describe the autoxidation of Amadori products (Thorpe and Baynes, 2003). Glucose can 
participate in oxidation reactions via a free carbonyl group present in its open chain form. If 
the reaction media contains oxygen, glucose has the ability to auto-oxidise and generate 
active oxygen compounds, such as peroxy radicals. These radicals form covalent bridges 
between proteins, thus altering their functions. The resultant production of glycation-derived 
free radicals is believed to play an essential role in the pathogenesis of diabetic complications 
(Giacco and Brownlee, 2010). 
In the human body, unbound metal ions promote glycoxidation and subsequent AGE 
formation. During this process, the hydroxyl radical is a key intermediate. This type of 
radical takes part in lipid peroxidation and formation of meta- and ortho-tyrosine (Figure 
1.7). Both tyrosine intermediates are unnatural and form exclusively in the presence of 
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hydroxyl radicals (Huggins et al., 1993). These radicals are generated in the presence of 
active metal ions, such as Cu+ or Fe2+ (Mn+), from hydrogen peroxide (Figure 1.8). 
 




Figure 1.8: Formation of hydroxyl radicals (Kaur and Halliwell, 1994). 
 
1.6 Factors affecting glycation 
Protein glycation was identified as leading to diabetic complications and a range of age-
related conditions (Brownlee, 2000). For this reason, factors affecting this reaction should be 
given a considerable amount of attention. The kinetics of the initial nucleophilic attack 
between the amino groups of proteins and the carbonyl group of reducing sugars ultimately 
depends on pH, oxygen, metal ions and the electrophilicity of the sugar carbonyl carbon 
(Bunn and Higgins, 1981). It was suggested that only a certain, small percentage of lysine 
groups enter the glycation reaction (Thorpe and Baynes, 1996). Low pKa in this region 
promotes initial glycation of this protein (Lin et al., 1998). Additionally, Amadori 
rearrangement was influenced by the presence of adjacent histidine groups, carboxylate 
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groups and negatively charged ions, such as phosphates, present in the reaction media. All 
these factors promote the chemical transformations the formed Amadori products undergo 
(Venkatraman et al., 2001). 
The formation of glycated proteins in vivo has been found to be dependent upon the inherent 
reactivity of specific amino groups, the half-life of the protein and the degree and duration of 
hyperglycaemia (Ahmed, 2005; Wautier and Schmidt, 2004).  
1.7 Characterisation of AGEs 
The glycation reaction leads to a series of compounds manifesting considerable structural 
diversity. Nevertheless, all AGEs can be classified into four groups based on their cross-
linking and fluorescent properties (yellowish-brown fluorescent colour) (Bousova et al., 
2005).  
1.7.1 Fluorescent cross-linked AGEs 
Reactions between basic groups of amino acids or Amadori intermediates and compounds 




Figure 1.9: α-dicarbonyl derivatives obtained during the course of glycation (Thornalley 
et al., 1999) 
 
The cross-links between proteins formed by the structures (Figure 1.9) are believed to be 
responsible for the adverse effects by AGEs during aging-related processes and diabetes. 
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Fluorescence and the ability to produce cross-links are the most important features of this 
class of compounds. The formation of cross-linked fluorescent AGEs is shown in Figure 
1.10. 
 
Figure 1.10: Formation of fluorescent cross-linked AGEs (Thornalley et al., 1999) 
The first isolated and characterised fluorescent cross-linked AGE, pentosidine, was obtained 
from collagen. The synthesis of this compound is possible through a reaction between 
arginine and lysine residues with most carbohydrates (Sell et al., 1999). Pentosidine is not the 




Figure 1.11: Examples of fluorescent cross-linked AGEs (Ulrich and Cerami, 2001) 
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1.7.2 Non-fluorescent cross-linked AGEs 
The highest proportion of AGEs is non-fluorescent AGEs with protein-protein cross-linking 
in vivo (Ahmed, 2005). The main AGE-structures belonging to this group are imidazolium 
dilysine cross-links also known as glyoxal-lysine dimer (GOLD) or methylglyoxal-lysine 
dimer (MOLD) cross-links (Chellan and Nagaraj, 1999). Examples of non-fluorescent cross-
linked AGEs are shown in Figure 1.12. 
 
Figure 1.12: Examples of non-fluorescent cross-linked AGEs (Ulrich and Cerami, 2001) 
1.7.3 Fluorescent non-cross-linked AGEs 
In addition to cross-linked AGEs, which can considerably influence the function and 
structure of proteins, a range of fluorescent non-cross-linked AGEs are detected in the blood 
of diabetic patients. These compounds may have adverse effects on possible protein cross-
linking. They also play the role of biological receptors promoting a variety of undesired 
changes at tissue and cellular levels (Niwa, 1999). The backbone of the organic linking 
fragment is similar to fluorescent cross-linked AGEs. The only exception is that one of the 
bonds connecting the heterocyclic part with the amino acid is substituted by the N-H bond 




Figure 1.13: Examples of fluorescent non-cross-linked AGEs (Niwa, 1999) 
1.7.4 Non-fluorescent non-cross-linked AGEs 
A number of non-fluorescent, non-cross-linked AGE structures arising from protein glycation 
have been described under physiological conditions. Carboxymethyllysine (CML) 
carboxyethyllysine (CEL), pyrraline and imidazolones (Paul et al., 1998) are the classical 
types within this group (Figure 1.15). Of the aforementioned AGEs, CML (Ikeda et al., 1996) 
and pentosidine are of particular importance in vivo and can be used as AGE accumulation 
markers throughout life and in diabetes (Dyer et al., 1993; McCance et al., 1993). 
 
 





1.8 Intracellular glycation and AGE formation 
The extent of intracellular glycation and subsequent AGE formation correlate inversely with 
a series of diabetic complications (Schalkwijk and Miyata, 2012). AGEs are generated via 
either lipid peroxidation or the oxidation of Amadori compounds. The dicarbonyl compound 
methylglyoxal generates via non-oxidative glyceraldehyde-3-phosphate fragmentation and 
generates the most important AGEs in the intracellular environment (Brownlee, 2005). 
Thiamine and benfotiamine play an important role during intracellular glycation. Thiamine is 
a highly powerful AGE inhibitor and benfotiamine, a thiamine pro-drug soluble in lipids, 
lowers the formation of AGEs (Balakumar et al., 2010; Hammes et al., 1999). 
Initially, it was believed that AGEs were only able to form exclusively on extracellular long-
lived macromolecules. This was because the rate of glycation was slow, and intracellular 
proteins simply would not occur within the time necessary to accumulate any measurable 
quantity of AGEs (Giardino et al., 1996). The extent of AGE production in endothelial cells 
that are the main location for hyperglycaemia damage is more significant. For instance, 
Giardino et al. (1994) established that after one week of culturing cells in media rich with 
glucose, the concentration of AGEs in endothelial cells increased 14-fold. This significant, 
rapid rate of AGE synthesis likely correlates with the hyperglycaemia-promoted formation of 
intracellular sugars. Compared with glucose, these sugars are much more reactive and include 
glyceraldehyde-3-phosphate, glucose-6-phosphate, methylglyoxal and fructose (Goldin et al., 
2006). 
Diabetes-related hyperglycaemia leads to a range of chemical alterations in intracellular 
metabolites, thus resulting in a series of diabetic complications (Cade, 2008). These 
alterations are reversible, but the damage done to the tissues and internal organs is not 
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(Bucala et al., 1993; Sakata et al., 2001). In addition, AGEs also enter the body through a 
range of exogenous sources, such as foods and cigarettes.  
 1.9 Exogenous sources of AGEs 
Curing tobacco leaves was suggested as a source of chemicals that considerably increase the 
in vivo concentration of AGEs. Glycotoxins obtained from cigarettes readily enter the alveoli 
where they penetrate lung cells and spread throughout the body via the blood stream. 
Glycotoxins interact with glycation products, thus contributing to overall AGE formation 
(Cerami et al., 1997). Similar conclusions were drawn in other studies indicating that tobacco 
smoke was a well-known and considerable source of AGEs (Peppa et al., 2003). Thus, the 
combustion of pre-AGEs found in tobacco smoke led to the formation of toxic and reactive 
AGEs in the human body. Consequently, it was established that AGE concentration was 
significantly elevated in the blood of smokers. As a result, diabetic smokers were reported to 
manifest higher AGE concentrations in their ocular lenses and arteries (Peppa et al., 2003). 
Heat is used worldwide for food treatment to improve its taste, bioavailability and safety. 
Along with a range of positive effects, overheating food can result in protein degradation as 
well as deteriorative, undesired reactions (Faist and Erbersdobler, 2001; Jaeger et al., 2010). 
In certain cases, heat treatment promotes the Maillard reaction, thus adding desired aromas, 
colours and flavours to food products. In particular, this reaction is widely exploited in 
baking bread, roasting coffee and the production of caramel. In addition, a range of Maillard 
reaction products is added to juices, sodas and other industrial products (Luevano-Contreras 
and Chapman-Novakofski, 2010; O'Brien and Morrissey, 1990).  
Unfortunately, the common Western diet has an increasing, exogenous source of AGEs 
(Richard et al., 2010). The overall content of these compounds in food products depends on 
the composition of nutrients in them. Thus, foods rich in fats and proteins present a higher 
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AGE content (Goldberg et al., 2004; Uribarri et al., 2010). The formation of AGEs is 
accelerated by elevating the time and extent of exposure to the increased temperature. 
Additionally, by using enzyme-linked immunosorbent assays (ELISA), it was established that 
nearly 10% of ingested AGEs enter the blood and circulate within the body. Two-thirds of 
this quantity remains covalently incorporated in tissues and organs. The remaining one-third 
leaves the body via the kidneys (Koschinsky et al., 1997). 
Most of Maillard reaction products that synthesise in vivo and enter the human body with 
food remain uncharacterised. Nevertheless, some of these compounds are dicarbonyl 
derivatives as well as pyrralines and furfurals derivatives (Ames, 2008). It was also 
established that regardless of AGE diversity, CML (N-epsilon-carboxymethyl-lysine) was the 
most abundant AGE. During analytical investigations of foods, CML is always among the 
first characterised AGEs. This compound is particularly abundant in milk and milk-
containing products. For this reason, CML was chosen as an AGE marker in food (Ames, 
2008). 
Regardless of whether AGEs form in vivo or enter the body via food or tobacco smoke, they 
express their biological properties via interaction with the receptor for advanced glycation 
end-products (RAGE). 
1.10 Biological effects of AGEs (receptor-dependent effects)  
RAGE is a compound belonging to the immunoglobulin group of receptors. In humans, the 
gene responsible for the expression of RAGE is located on the sixth chromosome, which is 
situated between Class II and III of the histocompatibility complex genes. The gene consists 




The mass of a typical RAGE molecule is 45-kDa. A significant part of this molecule is 
located within the cellular wall; however, an extracellular element is also present. The 
extracellular part of a RAGE molecule is composed of a variable (V-type) domain, which is 
followed by two constant (C-type) domains. The V-type domain is similar to the one found in 
immunoglobulin. RAGE possesses a single domain that runs from one side of the membrane 
to the other. The V-type domain has proven highly important in binding with organic ligands, 
and the constant domain cytosolic tail is crucial for RAGE-mediated signalling (Srikanth et 
al., 2011). In addition to full-length normal RAGE molecules, a series of truncated variations 
are found. The existence of these variations is explained by the presence of splice variants in 
the mitochondrial RNA. For instance, an N-truncated protein type does not possess the V-
type segment, but it is similar to normal RAGE proteins in all other features and is not 
excluded from the cell membrane (Basta, 2008). A schematic representation of RAGE is 
given in Figure 1.15. 
 




RAGE molecules are formed in a series of organs and tissues, but their highest concentration 
is in the skeletal muscles, the lungs and the heart. Additionally, this type of protein can be 
found in lymphocytes and macrophages. In vessels, RAGE is located in smooth muscle cells 
and endothelium (Koyama et al., 2007). AGE receptors play a critical role in the 
development of diabetes complications (Win et al., 2012). This conclusion was supported by 
investigations on experimental models. For instance, RAGE activation was shown to 
contribute to axonal sprouting, which is an accompanying development of the central nervous 
system. On the other hand, RAGE inhibition leads to depression of sciatic nerve functions 
and its regeneration (Huttunen et al., 2000). 
The most significant outcome of AGE-RAGE interaction is the activation of a series of 
biological mechanisms resulting in oxidative stress. The biological consequences of the 
AGE-RAGE interaction are summarised in Figure 1.16. 
 




The interactions of interest result in the promotion of prolonged inflammation as a direct 
result of the expression of pro-inflammatory chemokines and cytokines (Figure 1.16). The 
expression of both compounds is RAGE dependent. The first biological effect of the AGE-
RAGE interaction is the promotion of the reactive oxygen species (ROS). The first stages of 
ROS formation are influenced by the NAD(P)H-oxidase system. A recent investigation 
indicated that alterations in the sequence of amino acids responsible for RAGE formation 
result in alterations of the signal transmitted by the molecule inside the cell. Furthermore, the 
duration and intensity of the signal resulted in different signalling pathways employed by 
RAGE. These pathways and the corresponding outcomes are represented in Figure 1.16 
(Marchetti, 2009). 
Interaction with RAGE as well as AGE metabolism results in the formation of ROSs. These 
species are of paramount importance in promoting oxidative stress and further diabetic 
complications. 
1.11 Oxidative stress, free radicals and glycation 
Free radicals and oxidative stress are associated with a range of pathological conditions 
including atherosclerosis, Alzheimer’s disease, chronic inflammation and diabetes. In all 
these processes, ROSs are of paramount importance (Brieger et al., 2012; Rahbar and 
Figarola, 2003). Thus, oxidative stress is characterised by considerable imbalance between 
the formation of free radicals and their deactivation by natural defence mechanisms. This 
mechanism exists in all organisms and executes in order to prevent tissue damage and 
dysfunction. The excess quantity of free radicals is generated by cytochrome p450, 
mitochondria respiration, xanthine oxidase functions and RAGE-mediated processes (Lander 
et al., 1997). 
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It is being suggested that ROSs induce signalling in pathophysiological and physiological 
conditions. For instance, ROS production within certain biological boundaries is critical to 
sustained homeostasis (Rahbar and Figarola, 2003). Regardless where ROSs are produced 
and the conditions of their production, an elevated concentration of powerful oxidants has 
two outcomes: the activation of specific signalling mechanisms and damage to all cell 
components (Hensley et al., 2000; Kvietys and Granger, 2012). ROSs include a variety of 
chemicals, including hypochlorous acid (HOCl), hydroxyl radical (HO•), peroxyl radical 
(ROO•), alkoxyl radical (RO•), hydrogen peroxide (H2O2) and superoxide anions (O2•–) 
(Hensley et al., 2000; Rahbar and Figarola, 2003). 
Glycation presents one of the major sources of active α-dicarbonyl active intermediates and 
ROSs generated via non-oxidative and oxidative glycation pathways (Rahbar and Figarola, 
2003).  
The role of methylglyoxal in promoting the formation of free radicals is extensively 
documented. Thus, during the glycation reaction, methylglyoxal induces the synthesis of 
superoxide radicals, peroxynitrite, hydrogen peroxide and many other substances responsible 
for oxidative damage. Additionally, methylglyoxal is responsible for the increase in activity 
of pro-oxidant enzymes, such as p38 MAPK and NADPH oxidase, as well as the elevated 
expression of PPAR-α and JNK (Desai and Wu, 2008).  
Elevated concentrations of nitric oxide (NO) result in the extensive formation of peroxynitrite 
(ONOO∙). This ROS is a strong nitrating agent and a powerful oxidant. Generated during 
glycation, peroxynitrites have the ability to damage proteins and DNA molecules due to their 




AGEs promote oxidative stress through a range of mechanisms. First, AGEs catalyse the 
formation of growth factors and cytokines. In addition, these compounds are able to bind with 
their corresponding receptors (RAGE) and increase ROS generation. Furthermore, oxidative 
stress occurs because of the imbalance between ROS production and antioxidant defences 
(Tan et al., 2007). In endothelial cells, AGEs catalyse the synthesis of vascular cell adhesion 
molecules and intercellular adhesion molecules, and they elevate the activity of NF-kB, 
which leads to increased oxidative stress (Kikuchi et al., 2003).  
1.12 Diabetic complications and glycation 
Generally, complications associated with diabetes are of two types: macrovascular and 
microvascular. Although numerous studies have been conducted on this topic, the cause for 
the majority of diabetic complications is unclear. However, one possible cause is AGEs and 
their build-up on long-lived proteins. On the other hand, vascular complications of diabetes 
can be reduced through glycaemia management, which eventually lessens AGE formation 
(Ahmed and Thornalley, 2007; O'Sullivan and Dinneen, 2009).  
1.12.1 Advanced glycation end-products and microvascular complications 
The formation of AGEs can increase diabetic microvascular complications in animals and 
humans (McCance et al, 1993; Wada and Yagihashi, 2005). Features found in conditions 
with microvascular complications, which are pervasive, are an increase of vascular 
permeability and prothrombosis, coagulation of the basement membrane and a reduction in 
blood flow (Huebschmann et al., 2006). However, diabetes mellitus is largely responsible for 
microvascular complications with unsuccessful treatment (Karachalias et al., 2003). 
Moreover, conditions such as retinopathy, nephropathy and neuropathy (Peppa and Vlassara, 




1.12.1.1 Diabetic retinopathy 
Diabetic retinopathy is the main microvascular complication found in diabetes, and it can 
cause the loss of vision. Over a period of 20 years, all patients with type 1 diabetes suffer 
from retinopathy to a certain extent, while about 60% of patients with type 2 diabetes suffer 
from retinopathy (Fong et al., 2004). A number of in vivo and in vitro studies suggest that the 
main reason for the growth and expansion of retinopathy might be increased intracellular and 
extracellular AGEs in diabetes (Anitha et al., 2008; Sato et al., 2006). Moreover, AGEs 
exhibit a growth inhibitory action on pericytes thereby leading to pericyte loss, which is the 
earliest histological hallmark of diabetic retinopathy. This, in turn, induces basement 
membrane thickening, which significantly contributes to the breakdown of the inner blood-
retinal barrier (Assero et al., 2001; Stitt and Curtis, 2005). In addition, AGE formation can 
lead to abnormal proliferative reactions in retinal microvascular endothelial cells, which may 
result in the abnormal expression of endothelial nitric oxide synthase (eNOS) (Giacco and 
Brownlee, 2010; Hogan et al., 1992).  
1.12.1.2 Diabetic cataract 
Cataract is a major cause of visual impairment and blindness worldwide and is characterised 
by opacification of the lens. Furthermore, cataractogenesis can be caused by chronic 
hyperglycaemia (Crabbe, 1998; Franke et al., 2003). However, the mechanism responsible 
for diabetic cataract formation is unknown. Currently, the glycation theory is widely accepted 
as playing a key role in cataract development in the lens. Several studies report that the 
formation of AGEs on lens crystalline may cause protein oxidation cross-linking, and 
formation of high molecular weight aggregates responsible for cataract formation (Cheng et 
al., 2006; Linetsky et al., 2008). In addition, the development of a diabetic cataract can be 
caused by the glycation of channel proteins and sodium-potassium pump (Na/K-ATPase) 
(Gallicchio and Bach, 2010; Stevens, 1998). 
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1.12.1.3 Diabetic nephropathy 
Of diabetic patients, 40–50% suffer from diabetic nephropathy (Berger et al., 2003; Wolf, 
2004). This complication involves the coagulation of glomerular and tubular basement 
membranes along with the enlargement of the mesangial layer, which eventually leads to 
vascular occlusion, microvascular damage and fibrotic changes, thus causing 
glomerulosclerosis (Coughlan et al., 2005). This disease is responsible for death and 
morbidity in diabetic patients and often leads to end-stage renal disease (Mima, 2013; 
Yamagishi et al., 2007). Furthermore, animal and other clinical studies have shown that AGE 
formation interferes with renal destruction, which is related to hyperglycaemia (Brownlee et 
al., 1988; Forbes et al., 2005). However, nephropathy patients have increased AGEs, which 
could be due to decreased clearance in the kidney rather than increased production by 
glycation (Shimoike et al., 2000). Moreover, several studies with human subjects show 
higher levels of pentosidine (Hashimoto et al., 2010; Monnier et al., 2005) and CML 
(Beisswenger et al., 2013; Mao et al., 2003; Miura et al., 2003) in diabetic patients’ renal 
tissues regardless of end-stage renal diseases.  
1.12.1.4 Diabetic neuropathy 
Diabetic neuropathy occurs when the peripheral sensory and autonomic nervous systems are 
damaged (Magalhães et al., 2008). The formation of AGEs is regarded as the main 
biochemical pathway related to diabetic neuropathy (Fowler, 2008; Sugimoto et al., 2008; 
Zochodne, 2007). Furthermore, the AGE-modified peripheral nerve myelin is vulnerable to 
phagocytosis by macrophages, which leads to segmental demyelination (Shi et al., 2013). In 
addition, damaged regenerative activity in diabetic neuropathy due to glycation of the 
extracellular matrix proteins collagen and laminin alters the electrical charges and coagulates 




Increasing evidence suggests the interaction of AGEs with RAGE is involved in nerve 
dysfunction, which may play an inflammatory role in peripheral nerve damage, although their 
precise role remains unknown (Huijberts et al., 2008). Moreover, AGEs change the 
expression levels of the inducible form of nitric oxide synthase (iNOS), which in turn reduces 
blood flow in the nerve and induces hypoxia in the peripheral nerve (Jack and Wright, 2012; 
Wada and Yagihashi, 2005).  
1.12.2 Advanced glycation end-products and macrovascular complications 
Macrovascular complications in diabetes involve a broad spectrum of pathological changes 
affecting major blood vessels leading to structural and functional abnormalities. The 
glycation of wall components and functional changes initiate endothelial dysfunction and 
make artery walls harder or decrease vascular compliance, which leads to structural 
amendments. Moreover, atherosclerosis is believed to be fundamentally responsible for the 
high incidence of vascular diseases such as stroke, myocardial infarction and peripheral 
vascular disease (Rahman et al., 2007). 
1.12.2.1 Diabetes and atherosclerosis 
Atherosclerosis is known to be a chronic inflammatory disease caused by the contraction of 
arteries and the gradual development of lesions (Christian and Heidi, 2011). According to 
several studies, atherosclerosis develops in diabetic patients due to AGE formation (Jandeleit-
Dahm and Cooper, 2008; Schmidt and Stern, 2000; Vlassara and Palace, 2002; Yamagishi et 
al., 2005). Moreover, abnormal lipoprotein metabolism, protein cross-linking and matrix 
component changes may assist AGEs in accelerating the atherosclerosis process (Ahmed et 
al., 2009; Goh and Cooper, 2008). AGEs may induce atherosclerosis by oxidising low 
density lipoprotein (LDL). Moreover, glycated LDL uptake by macrophages contribute to the 
development of foam cell formation (Basta et al., 2004; Brown et al., 2005; Chang et al., 
2011). Furthermore, AGEs promote vasoconstriction by quenching NO (Pandolfi and De 
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Filippis, 2007). In addition, AGEs may also inhibit vascular repair after injury (Crauwels et 
al., 2000; Guo and Dipietro, 2010), increased endothelial dysfunction through interaction 
with RAGE (Hallam et al., 2010; Smit and Lutgers, 2004; Tan et al., 2002), neointimal 
proliferation along with more plaque destabilisation (Burke et al., 2004; Raposeiras-Roubin 
et al., 2013). Moreover, the interaction of AGEs with RAGE may also act as an essential 
element in the formation of atherosclerosis in diabetic patients (Jandeleit-Dahm et al., 2008; 
Yamagishi et al., 2005). Considering this, the activation of NF-kB and activator protein-1 
transcription factors in vascular cells by AGEs may contribute to the elevated expression of a 
range of genes associated with atherosclerosis, including VCAM-1, endothelin-1, 
inflammatory cytokines and PAI-1 (Inagaki et al., 2003; Laakso, 2010). 
1.13 Diabetes and impaired wound-healing (Angiogenesis) 
Angiogenesis can be defined as the process of forming novel capillary blood vessels 
(Egginton, 2010). In adults, the rate of this process is usually very low compared with other 
types of tissues. Physiological exceptions are found during wound healing and in the female 
reproductive system, where angiogenesis is strictly regulated (Egginton, 2010). Uncontrolled 
angiogenesis results in juvenile haemangioma, rheumatoid arthritis and diabetic retinopathy 
(Liekens et al., 2001). 
The proliferation of endothelial cells takes place during angiogenesis. A range of factors in 
the microenvironment surrounding forming blood vessels controls this process. These factors 
include influence from cytokines, the adjacent extracellular matrix and neighbouring cells. 
The complex interactions of these factors results in signals allowing the dividing cells to 
produce the required architecture (Nelson and Chen, 2003). 
The migration of endothelial cells is of paramount importance in angiogenesis. A range of 
factors, including mechanotactic stimuli, heptotactics and chemotactics, regulates this 
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process. Additionally, extracellular matrix degradation is necessary to enable further 
progression of the blood cells. Endothelial migration of cells involves three main 
mechanisms: chemotaxis, or the directed movement in the direction of a soluble 
chemoattractants gradient; haptotaxis, or a shift in the direction of an immobilised ligands 
gradient; and mechanotaxis, or the migration in the direction determined by external 
mechanical forces (Delgado et al., 2011; Lamalice et al., 2007). 
Following cell proliferation and migration, the newly formed endothelial cell outgrowth 
needs to organise into an adequate, three-dimensional, tube-shaped structure. This outgrowth 
is called primary capillary plexus, and its reorganisation leads to the formation of blood 
vessels. This process can be modulated and assessed in vivo by allowing endothelial cells to 
produce tubes on fibrin clots or collagen (Cai, 2012). 
As mentioned before, angiogenesis takes place during wound healing and tissue repair. The 
process of wound healing can be defined as the complete replacement of damaged or 
destroyed tissue by living tissue. It consists of two main components: repair and regeneration. 
Wound healing consists of four overlapping phases: initial bleeding, inflammation, cell 
proliferation and tissue remodelling (Bainbridge, 2013). 
During the wound-healing process, the bleeding phase is usually the shortest phase. The 
magnitude depends on the wound but is essential and normal. Large numbers of chemicals 
inhibit the following inflammatory phase. Inflammation expands rapidly within hours but 
resolves gradually over several weeks. The repair material generates during the proliferation 
stage. The onset is rapid, but it takes several weeks for the process to reach its full magnitude 
(Reinke and Sorg, 2012). The final stage of the wound-healing process is remodelling the 
produced tissue. It overlaps with the proliferation stage and begins 1–2 weeks after the injury 
(Culav, 1999; Guo and Dipietro, 2010). 
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Patients with DM suffer from impaired wound healing (Kolluru et al., 2012). Wound healing 
in diabetic patients is characterised by defective formation or deposition of the healing matrix 
(Lerman et al., 2003). In humans, diminished perfusion due to arterial diseases and peripheral 
neuropathy are known to contribute to impaired wound healing. During the normal wound-
healing process, apoptosis plays a critical role in the removal of granulation tissue as well as 
fibroblasts and minor blood vessels in the tissue. In contrast, the extent of apoptosis related 
process is increased in diabetic patients as a direct result of the elevated glucose 
concentration in the blood (Bao et al., 2009). In addition, increased glucose levels alter the 
properties of messenger RNA (mRNA), which leads to the formation of lower quantities of 
collagen, fibronectin and plasminogen activator inhibitor that results in delayed cell 
replication and excessive cell death (Baumgartner-Parzer et al., 1995). 
A growth factor is a natural chemical able to promote cell growth. In turn, fibroblast growth 
factor (FGF-2) plays a role in angiogenesis and wound healing via the regulation of cell 
differentiation and the proliferation of newly formed cells and their migration. FGF-2 binds 
to the surface of the cell and promotes the dimerisation of FGF receptors with the subsequent 
activation of tyrosine kinase receptors and autophosphorylation of the cognate receptors 
(Boilly et al., 2000). 
1.14 Measurement of glycation reaction products 
The determination of protein modification has always provided a challenge for biochemists. 
The complex nature of glycation combined with the fact that AGEs are a mixture of different 
structures has led to difficulty measuring them; the lack of internal standards leaves assays 
open to error, as they require a high degree of accuracy and reproducibility for each sample 
(Smit and Lutgers, 2004).  
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Various tests have been conducted qualitatively and quantitatively to determine the level of 
AGEs; some utilise a vital mechanism known as fluorescence spectroscopy in vitro and in 
vivo (Meerwaldt et al., 2008). In addition, immunochemical techniques, such as ELISA, are 
another means to describe AGE structures, which use specific polyclonal and monoclonal 
antibodies for AGEs (Lin et al., 2002). A method that has been extensively used in recent 
studies is mass spectrometry. Moreover, utilising matrix-assisted laser desorption ionisation 
time-of-flight mass spectrometry (MALDI-TOF-MS) peptide mapping is considered a useful 
technique to determine particular protein glycation products in vitro and in vivo (Kislinger et 
al., 2004; Niwa, 2006). Nonetheless, a separation assay method, such as SDS-PAGE, is used 
during the course of glycation research (Ahmad et al., 2007; Xie et al., 2011). 
1.14.1 Measurement of early glycation products 
The measurement of early-stage glycation products (Amadori products) is used in order to 
evaluate metabolic control in diabetic patients. The two parameters commonly used are 
glycated haemoglobin (HbA1c) and fructosamine.  
1.14.1.1 Glycated haemoglobin 
The number of methods employed in measuring HbA1c is ion exchange chromatography by 
High-performance liquid chromatography (HPLC), affinity chromatography (relies on the 
distinction of structure), immunochemical assays and spectroscopic methods (Kislinger et al., 
2004). However, the measurement of HbA1c is normally utilised to monitor glycaemia in 
diabetes. In addition, the International Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) has provided an approved reference method for measuring HbA1c in 
humans (Groche et al., 2003; Lai, 2008). The percentage of HbA1c molecules is a valuable 




1.14.1.2 Glycated serum proteins 
A colorimetric technique is generally employed by clinicians to measure fructosamine 
(Lapolla et al., 2005). The measurement of glycated serum proteins (fructosamine) is gaining 
acceptance as a procedure for time-averaged control of glycaemia in diabetic patients. Unlike 
HbA1c, fructosamine levels reflect the blood glucose concentration over the preceding 10–20 
days, thus responding more quickly to changes in diabetic therapy (Guillausseau et al., 1990).  
1.14.2 Measurement of intermediate glycation products 
Several studies show that people suffering from diabetes may have increased concentrations 
of plasma glyoxal and methylglyoxal as compared to non-diabetics (Brown et al., 2013; 
Khuhawar et al., 2006). In addition, the plasma of people suffering from diabetes have 
elevated levels of 3-deoxyglucosone (Niwa, 1999). In addition, the formation of AGEs found 
in diabetics increases along with rising levels of dicarbonyl compounds such as glyoxal, 
methylglyoxal and 3-deoxyglucosone (Ahmed and Thornalley, 2003). With the use of mass-
spectrometric methods, dicarbonyl compounds are quantitatively demonstrated. The 
estimation of dicarbonyl compounds is of interest in terms of evaluating oxidation processes 
occurring in glycated proteins.  
1.14.3 Measurement of AGEs 
Advanced glycation end-products were initially measured by spectroscopic and fluorimetric 
methods. However, these methods are not very specific and can only provide mere 
indications on the general trend of the glycation process (Brownlee et al, 1988). More 
recently, various investigators have developed ELISA methods using polyclonal and 
monoclonal antibodies (Cheng et al., 2005; Monnier et al., 2005). The limitation of this 
current methodology is, however, that no absolute AGE standard for quantitative analysis 
exists (Singh et al., 2001). AGEs are currently being identified as biomarkers for specific 
disease processes. In addition, CML and pentosidine are discovered in vivo (Ni et al., 2009). 
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CML and pentosidine levels found in diabetic patients were originally evaluated by GC/MS; 
however, the ELISA method has recently been used to measure the level of CML with anti-
CML monoclonal antibodies (Hartog et al., 2007). Furthermore, diabetic patients with 
nephropathy were found to have elevated levels of pentosidine (Kerkeni et al., 2012). 
Likewise, the high level of serum CML was discovered in patients with diabetes who also 
have retinopathy and/or nephropathy, in contrast to patients without these conditions (Jakus 
and Rietbrock, 2004; Vinik, 2011).  
1.15 Natural defence mechanisms against glycation 
The human body developed a range of cellular mechanisms to protect the body against 
glycation and the accumulation of AGEs. These mechanisms employ glyoxalase systems (I 
and II), glutathione and aldose reductase to detoxify reactive dicarbonyl compounds and to 
sequentially reduce AGE formation (Gomes et al., 2005; Thornalley, 1998). Additionally, a 
novel group of enzymes called Amadoriases catalyses the deglycation of Amadori products, 
thus defending against glycation (Gerhardinger et al., 1995; Kousar et al., 2012).  
Human FN3K (fructosamine-3-kinase) was shown to phosphorylate fructoselysine groups 
situated on glycated proteins and transform it into fructoselysine-3-phorphate. This 
compound breaks down spontaneously, thereby reversing the glycation reaction in its early 
stage (Lapolla et al., 2013; Szwergold et al., 2001). In addition, macrophages possess 
receptors, which enable them to identify and remove glycated proteins by endocytosis 
(Matsumoto et al., 2002; Vlassara et al., 1988). 
1.16 Natural glycation inhibitors 
Although many different natural compounds are currently under extensive study and analysis 
in vivo, few have successfully entered clinical trials. However, none of these compounds has 
so far been approved for clinical use. Recently, several studies have specified that dietary 
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supplementation with combined anti-glycation and anti-oxidant nutrients may be a safe and 
simple complement to traditional therapies aiming to prevent and target diabetic 
complications (Ahmad et al., 2007; Babu et al., 2006). For example, polyphenol compounds 
including garcinol from Garcinia indica fruit (Yamaguchi et al., 2000), Luobuma tea 
(Yokozawa and Nakagawa, 2004), and crisilineol from Thymus vulgaris (Morimitsu et al., 
1995) have shown to be potent inhibitors of AGE formation. In addition, rutin from tomato 
paste was found to inhibit glycation (Kiho et al., 2004) and autoxidative reactions 
(Cervantes-Laurean et al., 2006). Moreover, a number of anti-oxidant nutrients have been 
reported to have anti-glycation properties in vitro. For instance, the extract of green tea 
contains large amounts of tannins (flavonoids), which have been reported to inhibit AGE 
formation (Babu et al., 2007). Additionally, ranges of other AGE inhibitors were extracted 
from natural sources. These compounds include epigallocatechin-3-gallate, caffeic acid and 
chlorogenic acid, which are all commonly extracted from coffee beans and green tea. 
Examples of natural inhibitors also include capsaicin, hesperidin and quercetin (Popova et al., 




Figure 1.17: Naturally occurring glycation inhibitors (Popova et al., 2010) 
 
These compounds are not the only inhibitors found in nature. Historically, it was established 
that salicylate-based treatment had a positive effect on reducing the glycosuria manifested by 
diabetic patients. Moreover, N-acetyllysine and lysine proved to be beneficial in lowering 
albuminuria occurring during diabetes. Nevertheless, the first compound extensively studied 
in in vivo and in vitro experiments was aminoguanidine (AG). Originally, Chang et al. (2003) 
established that AG had the ability to inhibit fluorescence and cross-linking of aortic 
collagen. Later, the compound was demonstrated to mitigate a range of diabetic 
complications including vasculopathy, neuropathy and nephropathy (Thornalley, 2003). This 
compound did not affect hyperglycaemia but was able to deactivate reactive dialdehyde 
intermediates produced during glycation, thus demonstrating inhibitory properties 
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(Thornalley et al., 1999). In addition to being an excellent AGE inhibitor, AG was also found 
to deactivate ROSs, such as nitric oxide radicals. Nevertheless, AG had a range of side effects 
including anaemia and the elevated possibility of anti-nuclear antibody (ANF) development. 
Higher rates of renal-neoplastic and pancreatic tumours were detected in diabetic patients 
treated with aminoguanidine. As a result, complications associated with this compound 
forced the cessation of aminoguanidine treatments (Rahbar and Figarola, 2003). Along with 
natural glycation inhibitors, a range of their synthetic counterparts was developed (Figure 
1.18). 
 
Figure 1.18: Salicylic acid, N-acetyllysine, lysine and aminoguanidine (Rahbar and 
Figarola, 2003) 
 
Moreover, dipeptide carnosine discovered by Vladimir Gulevich a Russian scientist. It is 
been found in animal muscles and brain tissues. Several studies shows that carnosine might 
have an effective anti-glycating agent (Hipkiss et al., 1995; Hobart et al., 2004; Argirova & 
Argirov, 2003). The dipeptide has been shown to inhibit formation of protein carbonyls and 
cross-links induced by reducing sugars and other reactive aldehydes such as. Methylglyoxal 




1.17 Momordica charantia 
Momordica charantia (MC) is a vegetable and medicinal plant belonging to the 
Cucurbitaceae family that grows in the subtropical and tropical regions. This plant is also 
known as bitter melon, bitter gourd, balsam pear or karela (Grover and Yadav, 2004; Joseph 
and Jini, 2013). The bitter taste is common for all areas of this vegetable plant. A raw fruit, 
produced by the plant, presents an elongated, cucumber-shaped object. Initially, the fruit is 
dark green and gradually turns yellow-orange as it ripens. At maturity, it splits into several 
irregular parts pointing upwards or sideways (Figure 1.19). Seeds are released from the 
lowest part of the fruit (Lee et al., 2009).  
 
Figure 1.19: development stages of Momordica charantia (A)-Raw; (B)-Mature; (C)-
Ripe (Lee et al., 2009) 
 
Usually, fruits are collected from the MC when they are still immature. They are used 
extensively in traditional medicine to mitigate diabetes symptoms and to improve general 
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well-being. According to Lee et al. (2009), MC presents a highly promising plant with anti-
diabetic properties. In addition, MC demonstrates a range of other pharmacological and 
biological activities.  
The properties of MC have been investigated since the 1960s. Ranges of metabolites were 
extracted from the fruit of this plant and the seeds it releases. From the chemical point of 
view, primary metabolites present in the bitter melon are triterpenes, glycosides, phenolic 
acids, flavonoids, essential oils, minerals, soluble dietary fibres, crude proteins and fats. 
Additionally, raw fruits contain elevated doses of Vitamins A and C (Chen et al., 2009). 
Cucurbitane triterpenoids are the most important secondary metabolites present in MC. These 
substances, as well as aglycones, produce a range of beneficial biological effects, which are 
particularly important in obesity and diabetes. Additionally, cucurbitane triterpenoids have 
anti-oviposition, anti-feedant, anti-diabetic and anti-cancer properties (Baby and Jini, 2013). 
MC demonstrated anti-diabetic properties in diabetic rats by decreasing glucose 
concentrations and anti-hyperlipidemic effects (Kameswararao et al., 2003). Furthermore, a 
reviewer’s evaluation showed MC’s hypoglycemic effects in humans, although two studies 
did not show any effect on glucose levels (Deng, 2012). The existing investigations in this 
area were not consistent due to poor study design. Moreover, the exact nature of the anti-
diabetic compound has not been established yet.  
1.18 Charantin 
Charantin is one of the triterpenoids obtained from MC. This substance presents a typical 
triterpenoid of the cucurbitane type and has pronounced anti-diuretic properties.  
Pitipanapong et al. (2007) demonstrated that charantin could be used in diabetes treatment 
and could potentially replace conventional treatment. Charantin presents a mixture of two 




Figure 1.20: Chemical structures of charantin (Pitiphanpong et al., 2007) 
Pitiphanpong et al. (2007) established that the most efficient way of obtaining the charantin 
chemicals mixture was to use the pressurised liquid extraction method (PLE). However, 
HPLC has been suggested as a possible alternative. Using this approach, it is possible to 
extract charantin along with other substances from small or large dried MC fruit (Lee et al., 
2009). 
Anti-diabetic properties of the individual chemicals forming charantin were also investigated. 
The charantin mixture was separated and identified as stigmastadienol and sitosterol 
glycosides. These compounds were separately tested for in vivo hypoglycemic effects, but 
neither compound exhibited any notable effects on the glucose concentration. For this reason, 
it can be concluded that charantin, along with the two glycosides, may be formed by other 
unidentified components responsible for charantin activity (Baby and Jini, 2013). 
1.19 Aims of the study 
Ths aims of the study were: 
 To confirm and evaluate the antioxidant activities of MCP, MCF extracts and charantin in 
vitro.  
 To investigate and compare the effect of MCP, MCF and charantin extracts on the formation 
of AGEs in vitro. 
 To examine the effects of BSA-AGEs and MCP, MCF extracts and charantin on angiogenesis 
using BAEC in vitro.  
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Chapter 2 Materials and Methods 
2.1 Materials 
 1,1-Diphenyl-2-picryl-hydrazyl (Sigma, UK) 
 24-well, 48-welland96-well plates (Scientific Laboratory Supplies, UK) 
 2-Mercaptoethanol (Sigma, UK) 
 Acetic acid (Fisher Scientific International, UK) 
 Acrodisc 32 mm syringe filter with 0.2 µm membrane (Pall Corporation, UK) 
 Acrylamide/Bis solution 40% (Bio-Rad Laboratories, Germany). 
 Aluminium trichloride (Fluka, UK) 
 Ammonium persulphate (Sigma, UK) 
 Antibiotics: Pencillinand Streptomycin solution containing  L-glutamine (PSG) in 
0.9% NaCl (Sigma, UK) 
 Ascorbic acid (Sigma, UK) 
 BIO-RAD protein estimation kit (Bio-Rad laboratories, UK) 
 Blotting papers (Schleicher and Schuell, UK) 
 Bovine aortic endothelial cells, secondary cell line (Cell and Molecular Biology 
Research Laboratory, Manchester Metropolitan University, UK) 
 Bovine serum albumin (Sigma, UK) 
 Carboxymethyllysine antibody; Rabbit polyclonal antibodies to CML (Bioscience, 
UK) 
 Charantin (Xi'an Day Natural Tech, China) 
 Cheese cloth (Scientific Laboratory Supplies, UK) 
 ColorBurst™ Electrophoresis Marker for SDS-PAGE (Sigma, UK) 
 Coomassie brilliant blue (Sigma, UK) 
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 Cryotubes (Scientific Laboratory Supplies, UK) 
 Detoxi-gel endotoxin removal columns (Thermo Scientific, USA) 
 D-glucose (BDH, UK) 
 Dialysis tube size 3 (Visking, UK) 
 Dimethyl sulfoxide, DMSO (Sigma, UK) 
 Dulbecco’s modified Eagle’s medium, DMEM (Lonza SPRL, Belgium) 
 ECL1 and ECL2 kits (Amersham Biosciences, UK). 
 Eppendorf tubes (Scientific Laboratory Supplies, UK) 
 Ethanol (Fisher Scientific International, UK) 
 Ethylene diamine tetra acetic acid (Sigma, UK) 
 E-toxate kit for endotoxin measurement (Sigma, UK) 
 Ferric chloride (Sigma- Aldrich, UK) 
 Ferrous chloride (Sigma- Aldrich, UK) 
 Ferrous sulphate (Sigma- Aldrich, UK) 
 Ferrozine (3-(2-pyridyl)-5, 6-bis (4-phenyl-sulfonic acid)-1, 2, 4-triazine (Fluka, UK) 
 Fibroblast growth factor-basic, bFGF or FGF-2 (R & D Systems, USA) 
 Foetal bovine serum, FBS (Lonza, Belgium) 
 Folin-Ciocalteau reagent (Sigma, UK) 
 Fresh Momordica charantia (Local store, Manchester, UK) 
 Gallic acid (Sigma- Aldrich, UK) 
 Gelatine, 0.1% w/v (Sigma- Aldrich, UK) 
 Glycerol (BDH, UK) 
 Glycine (BDH, UK) 
 Glyoxalic acid (Fisher Scientific, UK) 
 Goat anti-Rabbit Immunoglobulin G (IgG) (Dako, UK) 
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 Hydrochloric acid (Sigma, UK) 
 Hydrogen peroxide (Sigma, UK)  
 IgG1 Isotype Control from murine myeloma (Sigma, UK) 
 Isopropanol (Sigma,UK) 
 ISOTON® II Diluent (Bekman Coulter, UK) 
 Lysozyme (Sigma, UK) 
 Mannitol (Sigma, UK) 
 Matrigel Basement Membrane matrix 10 ml (vWR, UK) 
 Methanol (Fisher Scientific International, UK) 
 Methylene blue stain (Sigma, UK) 
 Methylglyoxal (Sigma, UK)   
 N, N, N′, N′-tetramethylethylenediamine (Sigma, UK) 
 Nitrocellulose membrane (Scientific Laboratory Supplies, UK) 
 OxiSelect N-Epsilon CML Elisa Kit (Bioscience, UK) 
 Parafilm (Scientific Laboratory Supplies, UK) 
 Paraformaldehyde (Sigma, UK) 
 Phosphate buffer saline (Lonza, UK) 
 Plate sealers (R & D systems, USA) 
 Potassium ferricyanide (Sigma, UK) 
 Potassium phosphate mono- and di-basic anhydrous (Sigma, UK) 
 Protease Inhibitor Cocktail (Sigma, UK) 
 Rabbit anti-Mouse (Murine) IgG Mouse (Dako, UK) 
 Rabbit IgG secondary antibody, Goat polyclonal to Rabbit IgG (Abcam, UK) 
 Radioimmunoprecipitation assay buffer (Sigma, UK) 
 RAGE (E-1), Monoclonal Antibody (Insight, UK) 
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 Razor blades (Kratos analytical, UK) 
 Rutin (Sigma-Aldrich, UK) 
 Skimmed milk powder (Local store, Manchester, UK) 
 Sodium azide (Sigma, UK) 
 Sodium bicarbonate (Sigma, UK) 
 Sodium chloride (Sigma, UK)  
 Sodium cyanoborohydride (Fluka, UK) 
 Sodium deoxycholate (Sigma, UK) 
 Sodium dihydrogen orthophosphate anhydrous (BDH, UK) 
 Sodium dodecyl sulphate (BDH, UK) 
 Sodium hydroxide (BDH, UK) 
 Sodium salicylate (Sigma-Aldrich, UK) 
 Sterile needle (BD Plastipak, UK) 
 Thermanox plastic cover slips, 13mm diameter (Scientific Laboratory Supplies, UK) 
 Tissue culture flasks (T-25, and T-75 ) (Scientific Laboratory Supplies, UK) 
 Trichloroacetic acid (Sigma, UK) 
 Tris (hydroxymethyl) methylamine (BDH, UK) 
 Trypsin-10X (Sigma, UK) 
 Tween 20 solution (Sigma, UK) 
 VectaSpin 3 centrifuge tube filters (Sigma, UK) 
2.2 Equipment and software 
 Adobe illustrator CS4  
 Adobe Photoshop 7.0 
 Analytical balance (Sartorius Machatronics Ltd, UK) 
 Automated cell counter (Bio-rad, UK) 
42 
 
 Autovortex mixer SA1 (Stuart Scientific Co, UK) 
 Blender for fresh Momordica charantia (Kenwood limited, UK) 
 Blotter (Hoefer Semi-Phor) (Amersham Pharmacia Biotech, UK) 
 CE-4400 UV-VIS double beam scanning spectrophotometer (Cecil Instruments, UK) 
 Centaur 2 MSE centrifuge (Fisons Scientific Equipment, UK) 
 Centrifuge S415D (Eppendorf, Germany) 
 Class II microbiological safety cabinet (Walker safety cabinet Ltd, UK) 
 CO2 incubator for cell culture use (Lab Impex Research, UK) 
 Cross power 500 for electrophoresis (Atto, Japan). 
 Digital multi-channel pipettes (Eppendorf, Germany) 
 Dual gel casting electrophoresis chambers (Atto, Japan) 
 Eppendorf Centrifuges 5415 D (Eppendorf, Germany) 
 Fuji S2 Pro camera 
 G Box Chem HR 16 (gel documentation and analysis system) (Syngene, UK) 
 Gene tool image analyzer (Syngene, UK) 
 Grant-bio shaker POS-300 (Grant Instruments Ltd, UK) 
 Ice maker (P & S Refrigeration, UK) 
 Image J software analyzer (free on line software) 
 Inverted phase contrast microscope (Nikon TMS, Japan) 
 Laboratory freezer Bio cold (Scientific Laboratory Supplies, UK) 
 Laboratory fridge (Scientific Laboratory Supplies, UK) 
 Laboratory pH/mV/temperature meter AGB-75 (Medical Scientific Instruments, 
England). 
 LTE IP 30 incubator for glycation samples (Scientific Laboratory Supplier, UK) 
 Luminescence spectrometer model LS 30 (Perkin Elmer LAS Ltd, UK). 
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 Magnetic stirrer hotplate (Stuart Scientific Co, UK). 
 Media card reader (MISCO, UK)  
 Micro flow biological safety cabinet (Bioquell Ltd, UK) 
 Microplate reader,  96-well (Spectramax, Finland)  
 Microsoft office Excel 2003 (Microsoft, USA) 
 Mini-protein tetra system (Bio-rad, UK) 
 Multiskan Go plate reader (Thermo, UK) 
 Rotary evaporator RE100 (BUCHI, UK) 
 Rotatest shaker R100 (Luckman Ltd, UK) 
 Sigma laboratory centrifuge 3K10 for cell culture use (Howe, Germany) 
 Single threshold coulter counter (Beckman Coulter, UK)  
 Trans-blot SD semi-dry transfer cell (Bio-Rad Laboratories, Germany). 
 TC10 Automated cell counter (Bio-Rad Laboratories, Germany) 
 Ultrospec 2000 UV–VIS spectrophotometer (Pharmacia Biotech Ltd, UK) 
 Water bath for cell culture use  Grant JB series (Scientific Laboratory Supplies, UK) 
 Water de-ionizer (Millipore, UK)  
2.3 Solutions 
 Preparation of 30% acrylamide solution (solution A) for SDS-PAGE: Acrylamide 
(29.2 g) and N, N´-methylene-bis-acrylamide (0.8 g) were dissolved in 100 ml of 
distilled water.  
 Preparation of 10% ammonium persulphate (solution D) for SDS-PAGE: Ammonium 
persulphate (100 mg) was dissolved in 1 ml of distilled water.  
 Preparation of 1 mg/ml Bovine serum albumin (BSA) standard solution for the Bio-
rad protein assay: BSA (20 mg) was dissolved in 20 ml of distilled water.  
 Preparation of blocking buffer (1% BSA-TBST): BSA (1g) was dissolved in 100 ml 
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of Tris-buffered saline and tween-20 (TBST). The pH was adjusted to 7.4. 
 Preparation of destaining solution for SDS-PAGE: Methanol (250 ml) was added to 
acetic acid (70 ml) and the volume was made up to 1 L with distilled water. 
 Preparation of revelation solution for Western blotting membrane: Mixture in equal 
volume of ECL1 solution and ECL2 solution. 
 Preparation of electrode buffer (running buffer) for SDS-PAGE and Western blotting: 
Tris-base (12.02 g), SDS (4 g) and glycine (57.68 g) were dissolved in 2 L of distilled 
water. The buffer was stored at room temperature. 
 Preparation of 5% milk-TBST used as blocking buffer for Western blotting: Skimmed 
milk (5 g) was dissolved in 100 ml of TBST buffer. The pH was adjusted to 7.4. 
 Preparation of sample buffer for Western blotting: Tris-base (1.51 g), glycerol (20 
ml), SDS (4 g), 2-mercaptoethanol (10 ml) and bromophenol blue (0.004 g) were 
dissolved in 100 ml of distilled water. The pH was adjusted to 6.8 and stored at -20°C.  
 Preparation of sample treatment buffer for SDS-PAGE: Sodium dodecyl sulphate (0.1 
g), 2-mercaptoethanol (0.1 ml) and glycerol (2 ml) were added to 1 ml of solution C 
and the volume was made up to 10 ml with distilled water. 
 Preparation of separating solution for Western blotting analysis: Tris-base (45.5 g) 
and SDS (1 g) were dissolved in distilled water. The pH was adjusted to 8.8. The final 
volume of the buffer was made up to 250 ml with distilled water. 
 Preparation of separating gel solution for 10% SDS-PAGE:  Solution A (6 ml) and 
solution B (4.5 ml) were added to distilled water (7.5 ml) and mixed. Then, 
ammonium persulphate (80 µl) was added to the mixture. Gel polymerization was 
initiated by adding TEMED (10 µl) and allowed to set for 45 – 60 minutes. 
 Preparation of separating gel (12.5%) for Western blotting: Separating solution (2.5 
ml) was added to distilled water (4.2 ml) and mixed with 40 % acrylamide/bis-
45 
 
acrylamide solution (3.3 ml). Then, ammonium persulphate (100 µl) was added to the 
mixture. Gel polymerization was initiated by adding TEMED (10 µl) and allowed to 
set for 20 – 25 minutes. 
 Preparation of (0.05, 0.1 and 0.2 M) sodium phosphate buffer solution (pH 7.4): the 
acid component of the buffer (sodium dihydrogen phosphate) and the basic 
component (sodium hydroxide) were weighed out in a certain ratio according to the 
Henderson Hasselbalch equation. The desired volume was then accordingly adjusted 
with distilled water and the solution was mixed. The pH was adjusted to 7.4. Sodium 
azide (3 mM) was added to the mixture to prevent any bacterial growth. The buffer 
was stored at 4 °C. 
 Preparation of stacking gel (4.5%) for SDS-PAGE: Solution A (0.9 ml) and solution 
C (1.5 ml) were added to distilled water (3.6 ml) and mixed. Then, ammonium 
persulphate (20 µl) was added to the mixture. Polymerization was initiated by adding 
TEMED (10 µl). The gel was allowed to set for 30 minutes. 
 Preparation of stacking solution used for Western blotting: Tris-base (15 g) and SDS 
(1 g) were dissolved in distilled water. The final volume of the buffer was made up to 
250 ml with distilled water. The pH was adjusted to 6.8. 
 Preparation of staining solution for SDS-PAGE: Coomassie brilliant blue (2.5 g) was 
dissolved in methanol (500 ml) and acetic acid (100ml). The volume was made up to 
1 L with distilled water and then filtered.  
 Preparation of TBST buffer: Tris-base (2.422 g), NaCl (16.36 g), and Tween 20 (2 
ml) were dissolved in 2 L of distilled water. The pH was adjusted to 7.4. 
 Preparation of Towbin buffer: Tris-base (1.51 g), glycine (7.2 g) and SDS (0.167 g) 
were dissolved in 425 ml distilled water and 75 ml of methanol. The pH was adjusted 
to 8.3. Preparation of tracking dye solution for SDS-PAGE: Bromophenol blue (1 mg) 
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was dissolved in glycerol (0.1 ml) and mixed with 0.9 ml of distilled water. 
 Preparation of 0.5 M Tris-HCl buffer (solution C) for SDS-PAGE: Tris 
(hydroxymethyl) aminomethane (6.1 g), SDS (0.4 g) and HCl (4.2 ml) were dissolved 
in distilled water up to 1 L. The pH was adjusted to 6.8. 
 Preparation of 1.5 M Tris-HCl buffer (solution B) for SDS-PAGE: Tris 
(hydroxymethyl) aminomethane (18.2 g),  SDS (0.4 g) and  HCl (2 ml) were 
dissolved in distilled water. The pH was adjusted to 8.8. 
 Preparation of tubing dialysis: Appropriate length of tubing was cut and boiled in 
distilled water for 10 minutes. The tubes were stored at 4 °C in distilled water 
containing few drops of chloroform to prevent any bacterial growth. 
 Reconstitution of FGF-2: Sterile phosphate-buffered saline was added to the vial in 
order to prepare a working stock solution (100 g/ml). The carrier-free protein was 
immediately used upon reconstitution to avoid loss in activity. FGF-2 aliquots were 
stored at -20 °C. 
2.4 Methods  
2.4.1 Preparation of extracts 
Aqueous MC flesh and pulp extracts were prepared according to a modified method 
previously described (Virdi et al., 2003). Flesh and pulp of MC (130 mg) were extracted 
using methanol in a ratio of 1:10. The homogenization was done in a blender at the highest 
speed set with one minute burst for a sum of 12 minutes. The homogenized extract was 
filtered through cheesecloth. A rotary evaporator was used to evaporate methanol and any 
remaining methanol was evaporated using a water bath at 100 °C.  
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2.4.2 Preparation of AGEs 
Briefly, either BSA or lysozyme (10 mg/ml) was incubated at 37 °C with glucose (0.05-0.5 
M) or methylglyoxal (0.1 M) in sodium phosphate buffer (0.1 M, pH 7.4) containing 3 mM 
sodium azide for different time intervals (Mashilipa et al., 2011). The prospective inhibitors 
of AGE formation such as MCP extract, MCF extract and charantin were introduced into the 
incubation mixture simultaneously. Control sample was incubated under the same conditions 
without the addition of sugars or inhibitors. All incubations were carried out in triplicate. 
After incubation, un-reacted sugar was removed by dialysis against distilled water for 2 days 
at 4ºC. The aliquots were removed immediately and stored at -20ºC until analysis. Markedly, 
the removal of endotoxin from the glycated and non-glycated solutions was achieved using 
Detoxi-gel resin columns. BSA-AGE formation was assessed by measuring the absorbance at 
585 nm with a fluorescence spectrophotometer. The endotoxin level of the solution of BSA-
AGEs was estmated with an E-toxate kit based on Limulus Amebocyte lysate assay and was 
found to be below the detection limit (< 0.125 EU/mL). Moreover, BSA-AGEs were 
dissolved in DMEM and were accordingly filtered with the use of a sterile 0.2 μm filter. The 
endotoxin-free BSA-AGE solution was kept at -20°C. 
2.4.3 Preparation of carboxymethyllysine (CML) 
Carboxymethyllysine (CML)-modified protein was prepared based on an established method 
described by (Reddy et al., 1995). In brief, BSA (100 mg) was incubated at 37ºC for 24 hours 
with  Glyoxalic acid (3 mg) as well as NaCNBH3 (10 mg) in 0.2 M sodium phosphate buffer 
(10 ml, pH 7.8). To remove unbound sugars, the sample was dialysed against distilled water. 
Different concentrations (5-15 mg/ml) of MCP, MCF as well as charantin extracts were 
added to the mixture. After incubation, the aliquots were stored at -20ºC until analysis. 
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2.4.4 Protein dialysis  
The removal of unbound sugars following glycation was achieved using dialysis against 
distilled water. Samples of protein were delivered into the tubing of the dialysis system and 
dialysed against 2 litres of distilled water. The samples were stirred at 4ºC with 4–5 changes 
implemented over a two-day period. Following dialysis, samples were stored at -20 ºC.  
2.4.5 Protein estimation using Bio-Rad protein assay  
BSA was used at 1 mg/ml (1 μg/μl) as a standard protein for calibration. Protein lysate (10 μl) 
was mixed with distilled H2O (90 μl) in a bijoux tube. Bio-Rad protein assay (2 ml) was 
added to each tube. Absorbance of the protein solution was measured at 595 nm with a 




Figure 2.1: Calibration graph for protein measurement using the Bio-Rad method. 




2.4.6 Endotoxin removal from BSA-AGEs and extracts 
The Detoxi-gel resin column underwent regeneration through wash cycles with five resin-bed 
volumes of 1% sodium deoxycholate, and subsequently by 3-5 resin-bed volumes of basal 
DMEM. Bovine serum albumin-AGEs or natural extracts were diluted in DMEM containing 
red phenol (used a tracking dye) then added to the column. The flow of column was ceased 
when the samples filled the resin-bed from top to bottom. Following, incubation was carried 
out for 60 minutes at room temperature prior to samples being collected. In an attempt to 
achieve greater efficiency with a gravity-flow column, the samples emerged from the column 
after the void volume was collected.  
2.4.7 Determination of endotoxin content in BSA – AGE solutions 
BSA-AGE solutions were analysed to detect the remaining endotoxin content using E-toxate 
kit. Samples, water and endotoxin standards (100 l) were added to the endotoxin-free glass 
test tubes. Subsequently, E-toxate working solution (100 μl) was added to each tube by 
inserting a pipette to just above the contents, and the lysate was then allowed to flow down 
the side of the tube. The tubes were mixed gently and covered with parafilm®, and incubated 
for 1 hour at 37 °C. Following incubation, the tubes were gently inverted 180°C and observed 
for evidence of gelation. The formation of a hard gel was considered to be a positive test. All 
other results including soft gels, turbidity, and increased viscosity or clear liquid were 
considered to be negative tests. Notably, the amount of endotoxin level (EU/ml) was 
calculated using the following formula: 
Endotoxin (EU/ml) =1/ (Highest dilution of sample found positive) X Lowest concentration of 




2.4.8 Detection of AGE’s 
2.4.8.1 Measurement of cross-linked AGEs by SDS-PAGE 
Integrity and cross-linking of glycated proteins were determined by the extent of dimer and 
polymer formation in protein samples removed from cross-linking assays carried out in the 
presence of MCP, MCF and charantin extracts. The cross-linking efficiency was assessed 
using 10 % SDS-PAGE according to the method of Laemmli (1970). Protein samples were 
diluted 1:10 in 0.5 M Tris-HCl buffer, pH 6.8 containing 1 % (w/v) SDS, 1 % (v/v) 2-
mercaptoethanol and 20% (v/v) glycerine and then boiled for 5 minutes. Samples containing 
1–2 mg/ml of protein and standard molecular weight marker were loaded into the wells 
followed by 2–3 μl of bromophenol blue and then subjected to electrophoresis using the mini-
Protean® 3 apparatus. Gels were stained in a solution containing 0.25 % (w/v) Coomassie 
brilliant blue R, 50 % (v/v) methanol and 10 % (v/v) acetic acid. Gels were destained in a 
solution containing 25 % (v/v) methanol and 7 % (v/v) acetic acid. 
2.4.8.2 Image analysis of SDS-PAGE gels  
The gels were photographed using Gene snap programme from G Box Chem HR16 imaging 
system. Bands were compared within the same gel. Integrated Density (I.D) was measured to 
analyse the one dimensional electrophoretic gels and the percentage inhibition of cross-linked 
AGEs was calculated using the following formula: 
% inhibition = 100 x (I.D without inhibitor – I.D with inhibitor) / I.D without inhibitor 
2.4.8.3 Measurements of fluorescent AGEs 
The formation of AGEs was assessed by their characteristic of fluorescence emission spectra 
at 420 nm after excitation at 350 nm. Glycated samples (10 mg/ml) were thawed at room 
temperature and 0.2 ml of each sample were diluted in 1.8 ml of distilled water to give a 
solution with a final concentration of 1 mg/ml. Fluorescent measurements were carried out 
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using a fluorimeter. Fluorescence intensity standards were used to calibrate with quinine 
sulphate (1 ng/ml) in H2SO4 and monitor the performance of the instrument. Distilled water 
solution was used as a blank to zero the spectrophotometer. The fluorescence of AGEs was 
expressed in arbitrary units (AU) per mg of protein.  
2.4.8.4 Detection of CML using ELISA 
Samples (100 µl) were transferred to 96-well plates and incubated overnight at 4 °C, and 
wells were rinsed twice with 250 µl of PBS. Add 200 μl of assay diluent to the wells, plates 
were left for 2 hours at room temperature on an orbital shaker, and were then washed 3 times 
using 1X washing buffer. Diluted primary antibody (1:1000) of anti-CML-antibody (100 μl) 
was added to the wells and plates were left at room temperature for 1 hour incubation on an 
orbital shaker. Any unbound antibody was removed by washing the wells 3 times with 1X 
washing buffer. Diluted HRP conjugated-secondary antibody (1:1000) was added to the wells 
and plates were left at room temperature for 1 hour incubation on an orbital shaker. Any 
unbound secondary antibody was removed by washing 3 times with 1X washing buffer. A 
warm HRP substrate solution (100 μl) was added to the wells and the plate was left for 20 
minutes at room temperature. The enzyme reaction was stopped by adding a stop solution 
(100 μl) to each well and the absorbance was determined at 450 nm using a microplate 
reader. 
2.4.9 Methods for antioxidant activity of Momordica charantia 
2.4.9.1 DPPH radical scavenging capacity 
1, 1-diphenyl-2-picryl-hydrazyl (DPPH) free radical-scavenging activity of extracts was 
calculated according to a modified version of an established procedure (Tang et al., 2004). 
Different extracts of (15 mg/ml) MCP, MCF extracts and charantin were mixed with 0.5 ml 
of methanolic solution that includes DPPH radicals (0.1 mM) and kept at room temperature 
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for 30 minutes in the dark. The absorbance was measured at 517 nm with a 
spectrophotometer. Ascorbic acid was utilized as a positive control and the distilled water 
was used as a blank to zero the spectrophotometer. Free radical-scavenging activity (FRSA) 
was computed as [(A-B)/B*100] where: 
A= the absorbance of 0.5 ml of the extracts mixed with 0.5 ml of DPPH solution. 
B= the absorbance of 0.5 ml of the extracts mixed with 0.5 ml of methanol.  
2.4.9.2 Metal chelating activity 
The ability of MCP, MCF extracts and charantin to chelate ferrous ions (Fe2+) was assessed 
according to a modified version of an established procedure (Loizzo et al., 2012). Briefly, the 
reaction mixture was composed of 500 μl of extracts (5–15 mg/ml), 50 μl of FeCl2 (2 mM) 
and 600 l of deionized water. The mixture was shaken well and incubated at room 
temperature for 10 minutes. A volume of 100 μl of 5 mM ferrozine was then added, mixed 
and left for another 5 minutes to complex the residual Fe2+. The absorbance with the Fe2+ 
ferrozine complex was measured at 562 nm with a spectrophotometer. Ethylene diamine tetra 
acetic acid solution (EDTA) was used as a positive control and the distilled water was used as 
a blank to zero the spectrophotometer. The chelating activity of the extract for Fe2+ was 
calculated from the following formula: Chelating rate = [1 – (absorbance of the sample) / 
(absorbance of control)] ×100 %  
2.4.9.3 Hydroxyl radical scavenging activity 
The hydroxyl radical scavenging activity of MCP, MCF extracts and charantin were tested 
based on a modified approach previously described (Kubola and Siriamornpun, 2008). 
Hydroxyl radical trapping property was assessed by monitoring the hydroxylation of 
salicylate by the Fe3+-salicylate-H2O2 system. The reaction mixture was composed of 1 ml of 
FeSO4 (1.5 mM), 0.7 ml of H2O2 (6 mM), 0.3 ml of sodium salicylate (20 mM) and 1 ml of 
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extracts (5-15 mg/ml) and incubated for 1 hour at 37ºC. The absorbance was measured at 562 
nm with a spectrophotometer. Mannitol was used as a positive control and the distilled water 
was used as a blank to zero the spectrophotometer. The scavenging activity of hydroxyl 
radicals was calculated as follows: 
Scavenging activity (%) = [1 – (A1 – A2)/A0] x 100 
Where A0 was the absorbance of the control, A1 was the absorbance of the extract and 
A2 was the absorbance without sodium salicylate. 
2.4.9.4 Measurement of reducing power 
The reducing power of the MCP, MCF extracts and charantin were measured using a 
modified version of an established procedure described by Tsai et al., (2006). In brief, a 
volume of 2.5 ml of extracts (15 mg/ml) were mixed with 2.5 ml of 0.2 M sodium phosphate 
buffer (pH 6.6 ) and 2.5 ml of 1% K3Fe(CN)6. The mixture was incubated for 30 minutes at 
50 ºC. A volume of 2.5 ml of 10 % TCA (w/v) was added and the samples were centrifuged 
at 1000 rpm for 10 minutes. The supernatant (2.5 ml) was mixed with 2.5 ml of distilled 
water and 0.5 ml of 0.1% of FeCl3. The absorbance was measured at 700 nm. Blanks were 
prepared using distilled water without extracts to zero the spectrophotometer. Ascorbic acid 
was used as positive control.  
2.4.9.5 Measurement of total phenolic compounds 
The amount of total phenolic compounds in MCP, MCF extracts and charantin were 
estimated according to a modified version of an established procedure described by 
(Miliauskas et al., 2004). Briefly, aliquots of 1 ml of the ethanolic MCP, MCF and charantin 
extracts (10 g/l) were mixed with 5 ml of folin-ciocalteau reagent (diluted 10-fold), mixed 
and incubated for 3 minutes at room temperature. A volume of 5 ml of 10% Na2CO3 solution 
was added, and the mixture was incubated for 1 hour at room temperature. The standard 
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curve was prepared using (0 - 0.3 mg/ml) ethanolic gallic acid solution. The absorbance was 
measured at 760 nm and the final results were expressed as mg/g of gallic acid equivalents 
(GAE). A standard curve required is shown below. A phenolic compound in Momordica 
charantia extracts in gallic acid equivalents (GAE) was calculated as follows:                      
C= c * v / m 
Where: C total content of phenolic compounds, mg/g plant extracts, in GAE 
c: the concentration of Gallic acid established from the calibration curve (mg/ml) 
v: the volume of extracts (ml) 




Figure 2.2: The standard curve using ethanolic gallic acid solution 
Gallic acid (0 - 0.3 mg/ml) was used as a standard solution for phenolic contents. Each value 
represents the mean ± SD (n = 3). 
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2.4.9.6 Measurement of total flavonols 
The content of flavonols was determined by a colorimetric method according to a modified 
version described by Miliauskas et al. (2004). Briefly, Aliquots of 1 ml of ethanolic MCP, 
MCF extracts and charantin (10 g/l) were mixed with 1 ml AlCl3 in ethanol (20 g/l) and 3 ml 
(50 g/l) sodium acetate ethanol, the mixture was incubated for 1 hour at 20 ºC. The 
absorbance was measured at 440 nm. Blank sample were prepared without the extract. The 
standard curve was prepared using (0 - 0.5 mg/ml) rutin ethanolic solutions. Flavonols 
contents had been expressed in milligrams of rutin comparable per gram of extract. Total 
flavonols compound in Momordica charantia extracts in Rutin equivalents (RE) was 
calculated as follows:   X= C*V/m     
Where: X total content of flavonols compound, mg/g plant extracts, in RE 
c: the concentration of Rutin established from the calibration curve (mg/ml) 
v: the volume of extracts (ml) 
m: the weight of pure plant extracts (g) 
2.4.9.7 Measurement of total flavonoid 
The content of Flavonoid was determined by a colorimetric method according to a modified 
version described by Miliauskas et al. (2004). Briefly, a volume of 1 ml of ethanolic MCP, 
MCF extracts and charantin (10 g/l) was mixed with equal volumes of 2 % AlCl3 in ethanol 
(20 g/l). The mixture was shaken and incubated for 40 minutes at 20 ºC. The absorption was 
measured at 415 nm with a spectrophotometer. Blank sample was prepared without the 
extracts. Flavonoid contents were expressed in milligrams of rutin is equivalent per gram of 
extract. Total flavonoid compound in Momordica charantia extracts in Rutin equivalents 
(RE) was calculated as follows:   X = (A*m0*10)/ (A0*m) 
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where: X—flavonoid content, mg/g plant extract in (RE) 
A—the absorption of plant extract solution  
A0—the absorption of standard rutin solution 
m—the weight of plant extract, g 




Figure 2.3: The standard curve using ethanolic Rutin solution 
Rutin (0 - 0.5 mg/ml) was used as a standard solution for flavonoid and flavonols contents. 
Each value represents the mean ± SD (n = 3). 
2.4.10 Methods for cell culture 
2.4.10.1 Thawing of cells 
Cryotubes containing the frozen bovine aortic endothelial cells (BAEC) were taken from a 
liquid nitrogen container, and were carefully cleaned with 70% ethanol. The frozen cells were 
in a freezing medium containing 10% DMSO and 90% FBS. During the thawing process, the 
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medium was thawed until became liquid but still cold to prevent any cell toxicity effect of the 
DMSO, a cryo-protector agent. The cell suspension was transferred to a universal tube 
containing a cold complete 15% FBS medium. The suspension was centrifuged at 1300 rpm 
for 5 minutes. The supernatant was then discarded and the cell pellet was re-suspended in 1 
ml of warm fresh complete medium. Subsequently, cells were seeded in T-75 flasks and 
incubated at 37°C in a humidified atmosphere of 95% air and 5% CO2-incubator. 
2.4.10.2 Heat inactivation of foetal bovine serum (FBS) 
Frozen FBS bottle (previously stored at -20°C) was incubated in a water bath (at a 
temperature of 37°C) until the serum was totally thawed. The heat-inactivation of the foetal 
bovine serum proteins occurred for 30-45 minutes in the water bath at 56°C. Notably, every 
10 minutes, the bottle would be turned. Following this period, the bottle was taken out from 
the water bath and allowed to settle until it reached room temperature. Aliquots of heat-
inactivated serum (50 ml Falcon tubes) were stored at - 20°C.  
2.4.10.3 Preparation of complete medium supplemented with 15% FBS 
In order to prepare 500 ml of complete medium supplemented with 15% FBS, the following 
reagents were mixed as described in Table 2.1: 
 
Table 2.1: Preparation of culture medium supplemented with 15% FBS. 
Reagent Volume of medium (500ml) 
DMEM 420 ml 
FBS 75 ml 
PSG 5 ml 
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2.4.10.4 Preparation of serum-poor medium supplemented with 2.5% FBS 
Serum-poor medium (SPM) containing 2.5% FBS was prepared by diluting 15% FBS with 
DMEM (in 100 ml) as indicated in Table 2.2. 







2.4.10.5 Culture of bovine aortic endothelial cells 
Bovine aortic endothelial cells (BAEC) were given by Dr. Sabine Matou-Nasri (Cell and 
Molecular Biology Research Laboratory, Manchester Metropolitan University). The 
endothelial cells were previously characterised by the presence of the von Willebrand factor. 
In tissue culture T-75 flasks coated with 0.1% gelatine, BAEC were cultured in complete 
medium composed of 15% FBS-DMEM supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin and 100 g/ml streptomycin. The culture flasks were put at 37°C in a humidified 
atmosphere of 95% air and 5% CO2-incubator. 
2.4.10.6 Trypsinization and sub-culture of cells: 
Upon confluence being reached, the medium was removed and discarded from the T-75 flask.  
Then, the cells were washed with 10 ml of sterile PBS and incubated with 5–10 ml of 1X 
trypsin solution for 2-5 minutes at 37°C. When cell detachment was achieved by the 
enzymatic action of the trypsin, 5 ml of complete medium were added to the flask to 
counteract the activity of the trypsin. The cell suspension was centrifuged at 1300 rpm for a 
Reagents 2.5% FBS 
DMEM with PSG 
(0% medium) 
83.34 ml 
15% FBS 16.66 ml 
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period of 5 minutes at room temperature. After discarding the supernatant, the cell pellet was 
re-suspended in fresh complete medium, and then split at a ratio 1:2 before being seeded in 
new T-75 flasks for sub-culture, which corresponded to a new passage. Throughout all the 
studies, the cells were used between passage 4 and 12. 
2.4.10.7 Preparation of freezing medium: 
Freezing medium was composed of 90% FBS and 10% DMSO. For example, for 25 ml of 
freezing medium, 2.5 ml of sterile DMSO were added to cold FBS (22.5ml). To avoid any 
risk of contaminations, the freezing medium was filtered and stored at -20°C. Fresh freezing 
medium was defrosted shortly before use. 
2.4.10.8 Freezing of cells: 
Two cryotubes with an estimated 5 x 105 cells in freezing medium per cryotubes were 
prepared from the same confluent flask and stored at –20°C for a period of half-an-hour. 
Subsequently, they were either stored overnight at –80°C or stored for 1 hour in liquid 
nitrogen. The cells were subsequently moved into liquid nitrogen for long-term storage. 
2.4.10.9 Cell counting 
Cells were counted using a Beckman-Coulter counter and repeated three times for accuracy. 
Briefly, the cell suspension (0.05 ml) was diluted in isotonic solution (10 ml) in a counting 
chamber. Each cell count was based on the aspiration of 0.5 ml of cell suspension. Therefore, 
the cell concentration was calculated as follows: 
Cell number / ml = mean of three cell counts x dilution factor (200) / 0.5 ml 
2.4.10.10 Assessment of cell proliferation using the Coulter counter 
BAEC (2.5 x 104 / ml) were seeded in complete medium in 24-well plates (0.5 ml / well). The 
cells were incubated for approximately 4 hours, the time to adhere to the bottom of the well. 
Then, the complete medium was discarded and the cells were washed gently 3 times with 
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PBS. Fresh media supplemented with 2.5% FBS, defined as serum-poor medium (SPM), was 
added to each well. Different concentrations of BSA-AGEs, native BSA, MCP, MCF and 
charantin extracts were added to the wells for 72 hours incubation. MCP, MCF and charantin 
extracts were also tested in the presence of BSA-AGEs. FGF-2 (25 ng/ml), a pro-angiogenic 
growth factor, was used as positive control. Control wells with untreated cells cultured in 
complete medium were also included in the experiments. After 72 hours incubation, the cells 
were washed 3 times with PBS and trypsinized. The number of cells was counted using the 
Beckman-Coulter counter. Each experiment was carried out in triplicate, and repeated at least 
three times independently.  
2.4.10.11 Assessment of cell viability using automated cell counter  
BAEC (2.5x104 / ml) were seeded in complete medium in 24-well plates (0.5 ml / well). After 
4 hours incubation, the complete medium was discarded and the cells were washed gently 
with PBS (3 times). Fresh SPM was poured into each well. Different concentrations of BSA-
AGEs, BSA, MCP, MCF and charantin extracts were added to the wells. FGF-2 (25 ng/ml) 
was used as positive control. Control wells with untreated cells cultured in complete medium 
were included. After 72 hours incubation, the cells were washed 3 times with PBS and 
trypsinized. Cell sample (10 µl) was mixed in equal volume with trypan blue (10 µl), a cell 
viability dye excluded by live cells and took up by dead cells. The cell viability was assessed 
using TC10, an automated cell counter. Each experiment was carried out in triplicate, and 
repeated at least three times independently. 
2.4.10.12 Assessment of cell migration (wound healing assay) 
Sterilized Thermanox plastic coverslips were placed into each well of a 24-well plate. BAEC 
(1 x 105 /ml) were seeded in complete medium on each coverslip (0.5 ml / well). After 24 
hours incubation, at pre-confluence, the complete medium was replaced with SPM for a 
further 24-48 hour-incubation. Attached to the coverslip, the cell monolayer was washed with 
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PBS (3-4 times) then wounded on each side of the central area with a sterile razor blade 
producing straight edged cuts. The wounded cell monolayer was washed with PBS to remove 
cellular debris or dislodged cells then placed in a new 24-well plate containing fresh SPM. 
Different concentrations of BSA-AGEs, native BSA, MCP, MCF and charantin extracts were 
added to the wells. MCP, MCF and charantin extracts were also tested in the presence of 
BSA-AGEs. FGF-2 (25 ng/ml) was used as positive control. Control wells with untreated 
cells cultured in SPM were included in the experiments. After 18-24 hours incubation, the 
coverslips were rinsed 3 times with PBS, fixed in 100% ethanol for 5 minutes, and allowed to 
air-dry. Cells were stained with methylene blue for 5 minutes and excess stain was removed 
with distilled water. The plates were left to air-dry. Pictures of 5 random areas of each 
coverslip with straight edged cuts were taken using phase contrast microscopy (10X 
magnification). The migration of the cells into the cell denuded area was quantified by 
counting the numbers and the distance of migrated cells in each field of view. The distance of 
migration was determined using Image J software (http://rsbweb.nih.gov/ij/indix.html). Each 
experiment was carried out in triplicate, and repeated at least three times independently.  
2.4.10.13 Assessment of cell differentiation (Matrigel™ tube formation assay) 
Endothelial cell differentiation to form vascular tube-like structures is the final and key step 
of angiogenesis. About 24 hours before the experiment, the Matrigel™ matrix (a 
reconstituted basement membrane and reduced in growth factors) was transferred from the 
freezer to the fridge to thaw. Sterile yellow tips were placed in the freezer to avoid the gel 
polymerization. Matrigel™ and sterile Eppendorf tubes were placed on ice. After 
trypsinization of the cells and centrifugation, cells were re-suspended in 1 ml of complete 
medium. Then, 32 µl of BAEC (1 x 106/ml) were mixed with a volume of 8 µl of BSA-
AGEs, native BSA, MCP, MCF and charantin extracts at various concentrations and 40 µl of 
Matrigel™ at 4°C, on ice. MCP, MCF and charantin extracts were also tested in the presence 
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of BSA-AGEs. The addition of 8 µl of complete medium and FGF-2 (25 ng/ml) to the cells 
poured under a spot shape into two wells (35 µl / well) of a 48-well plate per each condition. 
The Matrigel™ was allowed to polymerise for 1 hour incubation. Following polymerization, 
500 µl of complete medium were added in order to cover each (un) treated cell/Matrigel™ 
spot. After 24 hours incubation, the cells were washed twice with PBS and then fixed with 
4% paraformaldehyde for 15 minutes. Using a phase contrast microscopy (100X 
magnification), the photomicrographs were taken with a digital camera.  
2.4.11 Western blotting    
2.4.11.1 Cell treatment and cell lysis for Western blot 
BAEC (3 x 105/ml) were seeded in complete medium in a 24-well plate (0.5 ml /well). After 
24 hours incubation, at pre-confluence, the medium was discarded, and the cells were washed 
with PBS (3 times). Fresh SPM was added to each well for further 24 hours incubation. MC 
extracts (10 µg /ml) were added to the cells for 10 minutes incubation. Promptly, at the end of 
the incubation, the medium was discarded, and the cells were rinsed with 500 μl of cold PBS. 
Ice cold radioimmunoprecipitation assay (RIPA) buffer (100 μl) was added to lyse the 
untreated cells (control) and cells treated with FGF-2 (positive control) or MC extracts. 
Gently the plate was shaken on ice for a few minutes, cells were scraped using a cell scraper. 
The total cells lysates were transferred to cold Eppendorf tubes on ice and stored at -20°C 
until used. 
2.4.11.2 Western blot 
The acrylamide gel was prepared by mixing 40% bis-acrylamide (3.3 ml) with distilled water 
(4.2 ml) and separating buffer (2.5 ml) in a universal tube. Ammonium persulphate (APS) 
solution (10%, 100 μl) was added followed by 10 μl TEMED solution and the separating gel 
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was left to polymerise for 25 minutes. A few drops of isopropanol were added on top of the 
mixture. Isopropanol was removed after 25 minutes and rinsed with plenty of distilled water. 
As much as possible, distilled water was removed using a piece of Whatman® filter paper 
and then the stacking solution was prepared in a second universal tube, by mixing 40% bis-
acrylamide (1.45 ml) with  distilled water (6.1 ml), and stacking buffer (2.5 ml). As 
previously, 10% APS (100 μl) was added followed by TEMED solution (10 μl) and the 
stacking gel was left to polymerise for 15 minutes. The combs, clamps, and gaskets were then 
removed carefully to avoid damaging the wells and the gel plates were inserted into the 
electrophoresis chamber. The chamber was subsequently filled with electrode buffer (25 mM 
Tris, 192 mM glycine, 0.1% SDS, pH 8.3) in the space between the two sets of glass plates. 
Protein samples, sample buffer and molecular weight marker were taken out from the freezer 
and left to thaw at room temperature. The amount of proteins of each sample was determined 
by Bio-Rad protein assay and was fixed at 15 g for equal protein loading into the wells. 
Equal volume of protein samples and 2X sample buffer were mixed in Eppendorf tubes. The 
tubes were placed in the boiling water for 15 minutes. The molecular weight marker (10 μl) 
and the protein samples (around 20 μl) were gently loaded. The sample buffer (20 l) was 
added to the first and the last well while in the second well, the molecular weight marker was 
added. The syringe was washed after loading the marker and after each sample. Samples 
containing (15 μg) protein (up to 20 μl solution), along with pre-stained molecular weight 
markers, were separated by SDS-PAGE (10% w/v) at 60V for 45-60 minutes, until the 
samples tracked with the bromophenol blue (from the sample buffer) reached the top of the 
separating gel. Then during the protein separation, the voltage was increased up to 200V for 
30-45 minutes, until the dye reached the bottom of the separating gel. 
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2.4.11.3 Blotting of gel  
Two nitrocellulose membranes and 12 pieces of blotting paper were soaked for 2 minutes in 
Towbin buffer, the transfer buffer. Stacking gels were removed from the separation gels and 
discarded. The gels were sandwiched separately. The sandwich was performed in an electro-
blotter for each gel in the following order: three pieces of blotting paper, one piece of 
nitrocellulose membrane, gel and at the top 3 pieces of blotting papers. Any bubbles within 
the sandwiches were removed by rolling a clean 5 ml tip over the sandwich. Proteins were 
transferred from the gel to the membrane with a current fixed at 40 mA for 1 gel or 90 mA 
for 2 gels, for one hour. 
2.4.11.4 Blocking the nitrocellulose membranes 
Membranes were blocked with 1% BSA-TBS Tween (pH 7.4) for 1 hour at room temperature 
on rotating shaker. The blocking buffer was discarded and 10 ml of primary antibody solution 
(1:1000) such as rabbit polyclonal anti-ERK1/2 and mouse monoclonal anti-p-ERK1/2 
antibodies were poured onto each nitrocellulose membrane, then left on a rotating shaker 
overnight at 4°C. The membranes were subsequently washed five times for 10 minutes in 
TBS-tween at room temperature. Then, each membrane was immersed in 10 ml of mouse 
anti-rabbit or rabbit anti-mouse horseradish peroxidase-conjugated secondary antibody 
solution (1:1000) diluted in TBS-tween containing 5% (w/v) de-fatted milk for ERK1/2 and 
p-ERK1/2, respectively. After 1 hour at room temperature on the rotating shaker, the 
secondary antibody solutions were discarded and the membranes were washed five times for 
10 minutes in TBS-tween. 
2.4.11.5 Development of nitrocellulose membranes 
In a dark room, the nitrocellulose membranes were immersed in enhanced 
chemiluminescence (ECL) solution. To prepare the ECL solution, 1 ml of solution-A was 
added to 1 ml of solution-B and kept in the dark room for five minutes at room temperature. 
65 
 
Then the reactive ECL solution (1 ml) was poured onto the membrane for one minute and the 
excess of the reagent was drained off from the membrane. To avoid the membranes drying 
out and to protect them from light, they were quickly wrapped in cellophane films and kept in 
a black box. The box containing the nitrocellulose membranes was taken to the G-Box for 
image analysis and the fluorescence intensities of the bands were quantified using image J 
analysis software. The results were semi-quantitative and compared to the control.  
2.4.12 RAGE neutralization 
2.4.12.1 Cell culture for Western blot   
BAEC (3 x 105 /ml) were seeded in complete medium in a 24-well plate (0.5 ml / well). 
When they reached pre-confluence, the medium was discarded, and the cells were washed 
with PBS. Fresh SPM was added to each well, and then 20 µg/ml of mouse polyclonal anti-
RAGE antibody or 20 µg/ml of its isotype control (IgG1) were added to the medium. After 2 
hours incubation, the cells were treated with BSA-AGEs, MCF, MCP and charantin extracts 
for 10 minutes incubation. The medium was subsequently discarded, and each well was 
rinsed with 500 μl of cold PBS. RIPA buffer (100μl) was added to each wells and kept on ice. 
Gently the plate was shaken on ice for a few minutes and the cells were scraped using a cell 
scraper. The total cells lysates were transferred to cold Eppendorf tubes on ice and stored at –
20°C until used. 
2.4.12.2 Assessment of cell differentiation after RAGE neutralization  
Matrigel™ and sterile Eppendorf tubes were placed on ice. T-75 flasks were washed with 
PBS then the cells were scraped to maintain intact the structure of transmembrane protein 
RAGE. After centrifugation, cells were re-suspended in 1 ml of complete medium. BAEC (1 
x 106 /ml) were mixed with 20 µg/ml of anti-RAGE antibody or with 20 µg/ml of isotype 
control (IgG1) and kept on ice for 1 hour. Then, the cells were handled in the absence or 
66 
 
presence of FGF-2, BSA-AGEs and natural extracts according to the Matrigel™ tube 
formation assay’s method as previously described (2.4.3.13). 
2.4.13 Statistical analysis  
Statistical analysis was made through using Microsoft Office Excel 2007. The results of each 
experiment are expressed as mean ± Standard Deviation. Data were analysed for statistical 
significance using Student t-test and ANOVA. Variations with p values ≤0.05 were 
considered statistically different. Each experiment was performed at least three times and 













Chapter 3. Antioxidant activities of Momordica charantia extracts 
3.1 Introduction 
Oxidative stress is the most important risk factor of the beginning of diabetes and its 
complications. Over the last decade, it has been proved that there is a strong relationship 
between oxidative stress and diabetes (Rains and Jain, 2011). It has been known that 
oxidative stress increased in insulin-dependent (type 1) and non-insulin-dependent diabetes 
(type 2) (Rahimi et al., 2005). Oxidative stress is increased by reactive oxygen species (ROS) 
with the free radical formation, also considered as key indicator of oxidative stress 
(Tabatabaei-Malazy et al., 2013). Glutathione and catalase are antioxidant enzymes mainly 
produced by the liver to counteract the effects of these reactive oxygen species. Moreover, 
natural antioxidant compounds can be extracted from external sources such as natural 
products (Okayama et al., 2006). It has been proposed earlier that antioxidant compounds 
found in MC extract exert a strong activity against oxidative stress (Mahomoodally et al., 
2012). In this chapter, the antioxidant activity of several MC extracts was assessed using 
different in vitro antioxidant assays. The content of flavonols, flavonoids and phenolic 
compound in various MC extracts was also determined in vitro leading to the establishment 
of the link between antioxidation activities and antiglycation of MC extracts. 
3.2 Aims and objectives 
The aim of the present study is to investigate and compare the antioxidant activities of MCP, 
MCF extracts and charantin in vitro.  
3.3 Methods 
Antioxidant activities of all MCP, MCF extracts and charantin were assessed using the DPPH 
as described in section (2.4.9.1). Hydroxyl radical-scavenging activity was assessed as 
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mentioned in section (2.4.9.3). Metal chelating activity of MCF, MCP and charantin was 
measured as explained in section (2.4.9.2). Reducing power of all extracts was also measured 
as described in section (2.4.9.4). The phenolic, flavonols and flavonoid contents of all 
extracts were also determined using methods as explained on sections (2.4.9.5), (2.4.9.6) and 
(2.4.9.7). 
3.4 Results  
3.4.1 Effect of MCP, MCF extracts and charantin on DPPH radicals: 
In the presence of MCP, MCF as well as charantin, the particular changes in colour from 
deep-violet to light-yellow and succeeding drop in absorbance of the constant DPPH radical 
were calculated at 517 nm on spectrophotometer. The percentage inhibitions were used to 
evaluate the protective effect of 15 mg/ml of MCP, MCF and charantin extracts on major 
DPPH search activity in vitro. All extracts were showed a significant (p< 0.001). Inhibition 











Figure 3.1: Effect of MCP, MCF extracts and charantin on DPPH radical scavenging 
activity. The bar graph shows the effect of 15 mg/ml of MCP, MCF and charantin on DPPH radicals. 
1,1-Diphenyl-2-picryl-hydrazyl radicals were prepared by dissolving DPPH in methanol. This 
solution was mixed with an equal volume of 15 mg/ml of MCP, MCF and charantin. The samples 
were kept in the dark for 15 minutes at room temperature and the decrease in absorption was 
measured at 517 nm. Ascorbic acid was used as positive control. Results are presented as mean ± SD 
(n=3).  *** p <0.0001 
 
3.4.2 Effect of MCP, MCF extracts and charantin on metal chelating activity: 
The ability of MCP, MCF and charantin to chelate transition metal ions has been screened by 
simply examining Fe2+-ion chelation. The metal chelating power of all extracts has been 
examined towards ferrous ions. In this assay, almost all extracts showed variable chelating 
activity since confirmed by simply their effectiveness within lowering ferrozine complex in 
dose dependent manner (p < 0.001). MCP possesses much more chelating activity in 





Figure 3.2: Metal chelation activity of MCP, MCF extracts and charantin. The bar graph 
shows the effects of different concentrations (5-15 mg/ml) of MCP, MCF extracts and charantin on 
metal chelation. Ethylene diamine tetra acetic acid was used as a positive control. Results are 
presented as mean ± SD (n=3). *** p <0.0001 
 
3.4.3 Effect of MCP, MCF extracts and charantin on hydroxyl radical scavenging 
activity: 
The actual scavenging abilities of MCP, MCF and charantin extracts on hydroxyl radical 
reserve from the 2- deoxyribose corrosion method. The results usually are mentioned as a 
percentage inhibition. All three extracts raise hydroxyl radical hunt in a dependent mode of 






Figure 3.3: Hydroxyl radical scavenging activity of MCP, MCF extracts and charantin. 
The bar graph shows the effect of different concentrations (5-15 mg/ml) of MCP, MCF extracts and 
charantin on hydroxyl radicals. Mannitol was used as a positive control. Results are presented as mean 
± SD (n=3). *** p <0.0001 
 
3.4.4 Effect of MCP, MCF extracts and charantin on reducing power: 
MCP, MCF and charantin at the concentration of 15 mg/ml showed significant reducing 
power as demonstrated by their effectiveness in reducing ferric ions to ferrous ions. The 
results clearly indicate that MCP, MCF and charantin extract have high reducing power 
compared to the control (Ascorbic acid) (Figure 3.4). In contrast, the lowest reducing activity 





Figure 3.4: Reducing power of MCP, MCF extracts and charantin. The bar graph shows 
the effect of 15 mg/ml of MCP, MCF extract and charantin on reducing power. Ascorbic acid was 
used as a positive control. Results are presented as mean ± SD (n=3). * p < 0.05, **p < 0.01 
 
3.4.5 Total phenolic content of MCP, MCF extracts and charantin: 
The substances of phenolic compounds (mg/g) in MC extracts were articulated in gallic acid 
corresponding (GAE). The results demonstrated that this overall phenolic amount in every 
component different significantly, the contents of total phenols in all extract as measured by 
Folin-Ciocalteau reagent in terms of gallic acid equivalent. The highest amount was found in 
MCF extract with a value of 175.33 ± 2.30 mg/g whereas for MCP extract was 134.66 ± 1.15 






Figure 3.5: Total amount of phenolic compound in MCP, MCF extracts and charantin. 
The content of phenolic compounds in 10g/l ethanolic MCP, MCF and charantin were expressed in 
gallic acid equivalents (GAE). Results are presented as mean ± SD (n=3). * p < 0.05 
 
3.4.6 Total Flavonols content of MCP, MCF extracts and charantin: 
The content of flavonols compounds (mg/g) in MC extracts were resolute and articulated in 
rutin equivalents. The concentration of flavonols mixed in a smaller amount as resemble with 
total phenolic and flavonoid. The highest amounts were found in MCP extract with a value of 
47.86± 0.91 mg/g, whereas for MCF extract was 41.11 ± 1.38 mg/g and charantin was found 





Figure 3.6: Total amount of Flavonols content in MCP, MCF extracts and charantin. 
The content of flavonols in (10g/l) ethanolic MCP, MCF and charantin were expressed in rutin 
equivalents. Results are presented as mean ± SD (n=3). **p < 0.01 
 
 
3.4.7 Total Flavonoid content of MCP, MCF extracts and charantin: 
The total of flavonoid substance of MCP, MCF and charantin mixture were moreover 
equivalent to rutin. This result, as presented in, showed that total flavonoid contents ranges 
from 134.67 ± 1.89 mg/g – 64.55 ± 2.03 mg/g. The flavonoid content in MCF extract was 





Figure 3.7: Total amount of flavonoid content in MCP, MCF extracts and charantin. 
The content of flavonoid in (10g/l) ethanolic MCP, MCF and charantin were expressed in rutin 
equivalents. Results are presented as mean ± SD (n=3). * p < 0.05 
 
3.5 Discussion 
In the present study, all extracts found to have antioxidant properties against DPPH radical 
with MCF have the most potent. These results supported the finding by Lin et al., (2011). The 
DPPH radical scavenging activity of phenolic compounds in MC extracts is because of their 
redox properties, which closely depends upon the chemical structure of the compound, the 
number of hydroxyl groups and the substitution pattern of hydroxyl groups (Roy et al., 2007). 
In a previous similar finding, MC extract has been shown to chelates Cu2+ ions and protects 
against LDL oxidation (Hsieh et al., 2005). The chelation activities of ferrous ions by MC 
extracts were assessed by measuring the absorption of ferrozine-ferrous complex. In the 
presence of ferrous chelating agents; the complex formation is disrupting and lead to the 
reduction of the red colour of the complex. Therefore, measurement of colour reduction 
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reflects an index of metal chelation activity of coexisting chelators (Chua et al., 2008). The 
hydroxyl radical is a strong reactive free radical produced in biological systems and has the 
power to damage the majority of biomolecules in living cells (Sim and Sil, 2008). The 
present study has revealed that all extracts can scavenge hydroxyl radicals in vitro in a dose 
dependent manner. Furthermore, MCF extract has better scavenger when compared with 
MCP and charantin extracts. It has been established that the reducing power might be linked 
with a polyphenol chemical substances, which were proven to apply antioxidant properties by 
donating a hydrogen atom (Kubola and Siriamornpun, 2008, Kumaran and Karunakaran, 
2007). The results of this study indicate that MCF and charantin extracts reduce ferricyanide 
complex to ferrous ions more efficiently when compared with MCP (Krishnaiah et al., 2011). 
The small antioxidant compounds of molecular weight, for instance polyphenols, flavonoids 
and flavonols, were found in MC (Gogi et al., 2010, Krishnaiah et al., 2011, Shan et al., 
2012). The results of the present study show that MCF extract which contains the maximum 
amount of phenolic substances show greatest antioxidant activity. Furthermore, MC may 
have antioxidant activities due to ascorbic acid (Vitamin C), Vitamin A and Vitamin E 
(Behera, 2005). The findings from these results confirmed that antioxidants properties 
correlate with antiglycation activities in some plants (Ahmad and Ahmed, 2006), in this 






Chapter 4. Antiglycation properties of Momordica charantia 
extracts 
4.1 Introduction 
High glucose levels in the body cause more AGE formation (Hsu and Zimmer, 2010). Over 
the past decade, there has been considerable interest in glycation and its role in the 
development of diabetic complications. The formation and accumulation of AGEs has been 
shown to play an important essential role in the pathogenesis of diabetic complications 
through (Jack and Wright, 2012). Therefore, in order to prevent diabetic complications, 
inhibitors of AGE formation may have an important role for future therapy. The uses of many 
plant-based preparations as oral hypoglycaemic agents have been subjected to scientific 
evaluation (Keter and Mutiso, 2012) including MC also known as the bitter gourd. MC is 
used for the management of several diseases including hypertension and diabetes. A number 
of researchers have examined the anti-diabetic properties of MC (Singh et al., 2011) and 
hypoglycaemic properties (Joseph and Jini, 2013). However, the antiglycation activity of MC 
has not been investigated yet.  
In this chapter, several methods were performed in vitro to compare the effects of MCP, 
MCF, and charantin on the formation of cross-linked AGEs. In addition, fluorescence 
measurement was used to identify and characterize the formation of fluorescent AGEs. To 
detect the effects of different MC extracts on inhibition of protein cross-linking, lysozyme 
dimerization by methylglyoxal followed by SDS-PAGE analysis was used. ELISA assay was 




4.2 Aims and objectives 
The aim of this study is to investigate and compare the effect of MCP, MCF and charantin 
extracts on the formation of AGEs in vitro.  
The objectives of this study are: 
 To identify and compare the effects of different concentrations of sugars and 
different period of incubations on fluorescent AGEs and formation of cross-linked 
AGEs in vitro. 
 To investigate and compare the ability of MCP, MCF and charantin extracts to 
inhibit the formation of cross-linked AGEs in vitro. 
 To study and validate the effect of MCP, MCF and charantin extracts on the 
formation of a named AGE ie CML in vitro using ELISA. 
 
4.3 Methods  
Lysozyme was glycated by incubating with different concentration of sugars in the presence / 
absence of MC extracts (section 2.4.2). The formation of fluorescent AGEs was assessed by 
their characteristic fluorescence (section 2.4.8.3). Cross-linked AGEs were assessed using 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) followed by 
Coomassie blue staining as described previously in section (2.4.8.1). CML was detected 
using ELISA as mentioned in section (2.4.8.4). 
4.4 Results 
4.4.1 Effect of different glucose concentrations on florescent AGE formation in vitro  
Effect of varying concentrations of glucose (0.05 – 0.5 M) on glycation of lysozyme in vitro 
was found by determining the intensity of fluorescence. Figure 4.1 illustrates the effect of 
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different concentrations of glucose on fluorescent AGE formation over 14 days. Subsequent 
analysis was made by using 0.5 M glucose. As shown in Figure 4.1, the fluorescence 
intensity of lysozyme incubated with glucose increased significantly (p < 0.01) as compared 
with the control. Magnitude of this effect depended on the concentration of glucose. The 
effect determined for lysozyme being incubated for 14 days with 0.5 M glucose was more 
than 9.2-fold greater as compared to control and 1.5-fold greater than the effect observed in 




Figure 4.1: The effect of different glucose concentration on fluorescent AGE formation 
in the lysozyme-glucose system. The bar graph shows the effect of different concentrations of 
glucose on fluorescent AGE formation. Lysozyme (10 mg/ml) was incubated with different 
concentrations of glucose (0 – 0.5 M) in 0.1 M sodium phosphate buffer of pH 7.4 at 37 °C for 14 




4.4.2 Effect of period of incubation on fluorescent AGE formation in vitro  
It has been determined during the study that the fluorescence intensity, an indicator of AGE 
production, increased gradually during incubation and reached its optimum level on 15th day. 
A significantly (p < 0.01) lesser intensity of fluorescence was demonstrated by the control 
lacking glucose as compared to the intensity determined in the presence of glucose from 3rd 
day to the last day of incubation. Fluorescence obtained in case of lysozyme incubation with 
glucose for 15 days was more than 12.1-folds greater as compared to control and 2-folds 
greater than the starting time of incubation (Figure 4.2).     
 
 
Figure 4.2: The effect of different incubation time on fluorescent AGE formation in the 
lysozyme-glucose system. The bar graph shows the effect of different incubation times on 
fluorescent AGE formation. Lysozyme (10 mg/ml) was incubated with glucose (0.5 M) in 0.1 M 
sodium phosphate buffer of pH 7.4 at 37 °C for 15 days. Each value represents the mean ± SD (n = 3), 
**p < 0.01. 
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4.4.3 Effect of different glucose concentration on cross-linked AGE formation in vitro  
The influence of different concentrations of glucose incubated with lysozyme on the cross-
linked AGE production over 15 days of incubation at 37ºC is shown in Figure 4.3. When 
glucose is incubated with lysozyme, cross-linked AGEs are produced that cause formation of 
dimers having a molecular weight of approximately 28 kDa as indicated by molecular weight 
markers (Figure 4.3, lane a). Decreased electrophoretic mobility with higher Mr as compared 
to control was observed with varying concentrations of glucose (Figure 4.3, lane c to h).  
 
 
Figure 4.3: The effect of different glucose concentration on cross-linking AGE 
formation in the lysozyme-glucose system. Gel showing lysozyme (10 mg/ml) incubated alone 
(lane b) or in the presence of different glucose concentrations (c) 0.5 M, (d) 0.4 M, (e) 0.3 M, (f) 0.2 
M, (g) 0.1 M and (h) 0.05 M in 0.1 M sodium phosphate buffer of pH 7.4 at 37 °C for 15 days. The 
cross-linked AGEs were analysed using SDS-PAGE and stained with Coomassie blue. The result is a 




The formation of cross-linked AGEs upon lysozyme incubation with glucose demonstrated 
significant (p< 0.05) increase in comparison with control as illustrated in Figure 4.4. This 
influence also depended on the dose of glucose. The cross-linked AGE formation was more 
than 24-fold greater when lysozyme was incubated for 15 days with 0.5 M glucose as 




Figure 4.4: The effect of different glucose concentration on cross-linked AGE formation 
in the lysozyme-glucose system. The bar graph shows the scanning of SDS-PAGE gel to show the 
effect of Lysozyme (10 mg/ml) with different concentrations of glucose (0 – 0.5 M) in 0.1 M sodium 
phosphate buffer of pH 7.4 at 37 °C for 15 days. Each value represents the mean ± SD (n = 3), * p < 
0.05. 
4.4.4 Effect of period of incubation on cross-linked AGE formation in vitro  
Adequate quantity of cross-linked AGEs was produced when lysozyme was allowed to react 
with glucose for varying incubation periods. The control sample contained lysozyme only 
(Figure 4.5, lane b). In comparison with the control, decreased electrophoretic mobility due to 
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greater relative molecular weight (Mr) was demonstrated by glycated lysozyme at different 




Figure 4.5: The effect of different incubation time on cross-linking AGE formation in 
the lysozyme-glucose system. Gel showing lysozyme (10 mg/ml) incubated alone (lane b) or in 
the different incubation time (c) 15 days, (d) 12 days, (e) 9 days, (f) 6 days, (g) 3 days and (h) 0 day 
with glucose in 0.1 M sodium phosphate buffer of pH 7.4 at 37 °C for 15 days. The cross-linked 
AGEs were analysed using SDS-PAGE and stained with Coomassie brilliant blue solution. The result 
is a representative figure of at least three independent experiments. 
 
It is evident from the scanning of this gel as shown in Figure 4.6 that the formation of cross-
linked AGEs was significantly (p< 0.05) increased in comparison with control sample and 
this occurred in a dose dependent manner as earlier. The formation of cross-linked AGEs was 
more than 60 folds greater when lysozyme was incubated with glucose for 15 days as 





Figure 4.6: The effect of different incubation time on cross-linking AGE formation in 
the lysozyme-glucose system. The bar graph shows scanning of SDS-PAGE gel to show the effect 
of lysozyme (10 mg/ml) with glucose at different incubation times (0 – 15  days) in 0.1 M sodium 
phosphate buffer of pH 7.4 at 37 °C. Each value represents the mean ± SD (n = 3), * p < 0.05. 
 
4.4.5 Effect of MCP on methylglyoxal-derived AGEs: 
Methylglyoxal reacts with lysozyme at a faster rate compared to glucose leading to 
production of adequate amount of cross-linked AGEs within 3 days of incubation and causes 
the formation of trimers as well (Figure 4.7, lane b). Varying concentrations of MCP (5-15 
mg/ml) were used for the assay. Since the formation of dimers was inhibited by MCP during 
the assay, the quantity of dimerized lysozyme was decreased in a dose- dependent manner 




Figure 4.7: Gel showing the effect of MCP on methylglyoxal-derived AGEs. Lysozyme 
(10 mg/ml) incubated alone (lane a) or in the presence of 0.1 M methylglyoxal  (lane b) in 0.1 M 
sodium phosphate buffer of pH 7.4 at 37 °C for 3 days. The inhibition of dimer formation was 
determined using different concentrations of MCP (c) 5 mg/ml, (d) 10 mg/ml and (e) 15 mg/ml. The 
cross-linked AGEs were analysed using SDS-PAGE and stained with Coomassie brilliant blue 
solution. The result is a representative figure of at least three independent experiments. 
 
A significant (p < 0.001) inhibition of cross-linked AGE formation was demonstrated by 
MCP extract in vitro when compared to the control. This inhibition depended on the 
concentration of MCP extract as the highest inhibition (49%) was determined in reaction 







Figure 4.8: The effect of MCP on methylglyoxal-derived AGE formation. The bar graph 
shows scanning of SDS-PAGE gel to show the effect of MCP on crosslinked AGE. Lysozyme (10 
mg/ml) was incubated with methylglyoxal (0.1 M) in 0.1 M sodium phosphate buffer of pH 7.4 at 37 
°C for 3 days. The percentage inhibition of methylglyoxal-derived AGE formation was determined 
using different concentrations of MCP. Each value represents the mean ± SD (n = 3), * p < 0.05, **p 
< 0.01, *** p < 0.0001. 
4.4.6 Effect of MCF on methylglyoxal-derived AGEs: 
The glycation mixture was incubated with varying concentrations of MCF for three days. 
Generation of dimers was inhibited substantially depending on the concentration of MCF. 
40%, 55% and 88% inhibition was caused by 5, 10 and 15 mg/ml of MCF respectively as 
shown in Figure 4.9, lanes c to e. A reaction mixture containing methylglyoxal and lysozyme 
was taken as a positive control in which dimers and trimers were generated in the absence of 




Figure 4.9: Gel showing the effect of MCF on methylglyoxal-derived AGEs. Lysozyme 
(10 mg/ml) incubated alone (lane a) or in the presence of 0.1 M methylglyoxal  (lane b) in 0.1 M 
sodium phosphate buffer of pH 7.4 at 37 °C for 3 days. The inhibition of dimer formation on protein 
cross-linking was determined using different concentrations of MCF (c) 5 mg/ml, (d) 10 mg/ml and 
(e) 15 mg/ml. The cross-linked AGEs were analysed using SDS-PAGE and stained with Coomassie 
brilliant blue solution. The result is a representative figure of at least three independent experiments. 
 
 
Formation of cross-linked AGEs in vitro was significantly (p < 0.01) inhibited by MCF 
extract as compared to the control sample and this inhibition was dependent on MCF 
concentration as optimum (88%) inhibition was observed in the sample with 15 mg/ml of 





Figure 4.10: The effect of MCF on methylglyoxal-derived AGE formation. The bar graph 
shows the effect of MCF on cross-linked AGE. Lysozyme (10 mg/ml) was incubated with 
methylglyoxal (0.1 M) in 0.1 M sodium phosphate buffer of pH 7.4 at 37 °C for 3 days. The 
percentage inhibition of methylglyoxal-derived AGE formation was determined using different 
concentrations of MCF. Each value represents the mean ± SD (n = 3), * p < 0.05, **p < 0.01. 
 
4.4.7 Effect of charantin on methylglyoxal-derived AGEs: 
The impact of varying concentrations of charantin (5-15 mg/ml) on the generation of cross-
linked AGEs is shown in Figure 4.11. When 0.1 M methylglyoxal was incubated with 
lysozyme (14 kDa, lane b), a considerable quantity of cross-linked AGEs were generated 




Figure 4.11: Gel showing the effect of charantin on methylglyoxal-derived AGEs. 
Lysozyme (10 mg/ml) incubated alone (lane a) or in the presence of 0.1 M methylglyoxal  (lane b) in 
0.1 M sodium phosphate buffer of pH 7.4 at 37 °C for 3 days. The inhibition of dimer formation on 
protein cross-linking was determined using different concentrations of charantin (C) 5 mg/ml, (d) 10 
mg/ml and (e) 15 mg/ml. The cross-linked AGEs were analysed using SDS-PAGE and stained with 
Coomassie brilliant blue solution. The result is a representative figure of at least three independent 
experiments. 
 
The inhibitory effect of charantine on generation of cross-linked AGEs was found to be 
dependent on concentration of charantin and the optimum inhibition (55%) was caused by 





Figure 4.12: The effect of charantin on methylglyoxal-derived AGE formation. The bar 
graph shows scanning of SDS-PAGE gel to show the effect of charantin on cross-linked AGE. 
Lysozyme (10 mg/ml) was incubated with methylglyoxal (0.1 M) in 0.1 M sodium phosphate buffer 
of pH 7.4 at 37 °C for 3 days. The percentage inhibition of methylglyoxal-derived AGE formation 
was determined using different concentrations of charantin. Each value represents the mean ± SD (n = 
3), **p < 0.01, *** p < 0.0001. 
 
4.4.8 Effect of MCP, MCF and charantin on CML levels using ELISA: 
Compared to the control containing BSA-CML, significant inhibition (p< 0.01) was 
demonstrated by all of the extracts with maximum inhibition by the MCF extract. Moreover, 
the inhibition depended on the concentration of extracts (Figure 4.13). MCF at the 
concentration of 5 and 15 mg/ml significantly inhibited  CML formation by 37% and 61% 
respectively. MCP at the same concentration 5 and 15 mg/ml decreased CML formation by 





Figure 4.13: The effect of MCP, MCF and charantin on CML formation as measured by 
ELISA. The bar graph shows the inhibition effect of MCP, MCF and charantin on CML levels were 
determined in the presence of different concentrations (5 and 15 mg/ml) of MCP, MCF and charantin 
extracts. Results are presented as mean ± SD (n=3), **p<0.01. 
4.4 Discussion 
DM is one of fastest growing diseases in the world. It is been reported that up to one-third of 
diabetes patients use alternative medicines. MC is one of the most popular plant using as anti-
diabetic agent (Joseph and Jini, 2013). Protein glycation in vitro was investigated in the 
current study by incubating proteins with sugars at physiological pH; however, non-
physiological concentrations of sugars were also employed to increase the rate of formation 
of AGEs in a shorter time period. Lysozyme serves to be an efficient protein model for 
determination of cross-linked AGE generation since oligomerisation occurs readily and can 
be measured conveniently following scanning of SDS-PAGE gels. Numerous earlier studies 
have also explored glycation of lysozyme in vitro (Kislinger et al., 2004). In this chapter, the 
findings show that increase cross-linked AGEs correlate with glucose concentration and the 
period of incubation. It is believed that the accumulation of cross-linked AGEs in tissues and 
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plasma is thought to be responsible for the long-term complications related to diabetes and 
ageing (Brownlee, 1995, Nimbalkar et al., 2012). The measurements of fluorescence to study 
the effects of different glucose concentrations and different period of incubation on AGE 
formation also supported the previous finding with SDS-PAGE gels. Methylglyoxal (α-
dicarbonyl) was chosen to complete the other experiments because it is highly reactive and 
contain the carbonyl groups (aldehyde/ketone). In addition, methylglyoxal has the ability to 
bind with sulfhydryl, amino, lysine, arginine and guanidine functional groups in proteins 
(Goldin et al., 2006). This study showed for the first time that MCP, MCF and charantin 
extracts have significant potential inhibition to the formation of AGEs in a dose-dependent 
manner in vitro. The most common AGE generated by oxidation reactions and glycation is 
carboxymethyllysin (CML) (Fujiwara et al., 2011). Animal and human tissues have increased 
concentrations of CML in skin collagen in diabetes and aging (Dyer et al., 1993, Kamata et 
al., 2009). The current study established that CML formation inhibited by MCP, MCF and 
charantin extracts with the MCF extract having the most potent effect. Several studies 
showed that MC significantly lowers the glucose level in diabetic patients and diabetic rats 
(Joseph and Jini, 2013, Waheed et al., 2006). In this regards, MC could stop AGE formation 
by lowering the glucose level. Numerous studies established that MC comprises of several 
amino acids that could decrease the generation of AGEs by blockage of carbonyl groups 
(Kim, 2009, Mahomoodally et al., 2012). Moreover, it is indicated that the abilities to inhibit 
the formation of AGE is linked to the plant extracts antioxidant properties to scavenge 
radicals formed during the Maillard reaction which forms the basis of glycation (Boo et al., 
2012, Shan et al., 2012). In the present study, extracts, which were found to have antioxidant 
properties against free radical activity, were also seen to possess antiglycation potential. 
Indeed, this protection against glycation-induced crosslinking may be due to the ability to 
chelate transition metals thus preventing autoxidative glycation and glycoxidation reactions. 
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In previous studies, MC extract has been shown to chelates Cu2+ ions and protects against 
LDL oxidation (Hsieh et al., 2005). The small antioxidant compounds of molecular weight, 
for instance polyphenols, flavonoids and flavonols, were found in MC (Gogi et al., 2010, 
Shan et al., 2012). The results of the present study show that MCF extract, which contains the 
maximum amount of phenolic substances, shows greatest antioxidant activity, therefore, 













Chapter 5. Pro-angiogenesis effect of Momordica charantia  
5.1 Introduction  
Angiogenesis refers to the process of a new blood vessels formation from existing blood 
vessels and is essentially important for physiological and pathophysiological situations such 
as female of the reproductive cycle, embryogenesis and wound healing (Ferrara and Kerbel, 
2005; Giuliano and Pagès, 2013). It had been established earlier that the generation of 
advanced glycation endproducts (AGEs) plays a crucial role in causing diabetic vascular 
complications. Moreover, numerous research studies have determined that wound-healing 
can be impaired due to the accumulation of AGEs (Huijberts et al., 2008). In this connection, 
MC is known for its potential to speed up, improve the wound healing process (De Nardo et 
al., 2013), and increase beta cells proliferation (Ahmed et al., 1998). All the main steps of 
angiogenesis can be simulated in vitro by studying endothelial cells in basic angiogenic 
assays including tube formation, cell proliferation and migration assays. Thus, bovine aortic 
endothelial cells (BAEC) were cultured and treated with either BSA-AGEs and MC extracts 
or both. The receptor for AGEs (RAGE) was neutralized to demonstrate whether MC extracts 
kept its angiogenic effects. 
 
5.2 Aims and objectives  
The aim of this work was to examine the effects of BSA-AGEs with Momordica charantia 
extracts on angiogenesis using BAEC in vitro.  
The objectives of this study were: 
 To investigate the effect of native BSA, BSA-AGEs and MC extracts on BAEC 
proliferation using the Coulter counter. 
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 To investigate the effect of MC extracts on anti-angiogenic effect of AGEs on 
BAEC proliferation using the Coulter counter.  
 To determine the cytotoxicity effects of BSA-AGEs or MC extracts on BAEC using 
automated cell counter (Bio-Rad, UK). 
 
 To identify the potential effect of native BSA, BSA-AGEs and Momordica 
charantia extracts on BAEC migration and tube formation using wound healing and 
the Matrigel™ assay  
 
 To identify the potential effect of MC extracts combined with BSA-AGEs on 
BAEC migration and tube formation using wound healing and the Matrigel™ 
assay, respectively. 
 
 To investigate the angiogenic signalling pathways induced by Momordica 




BAEC were used to investigate the effect of MC extracts in the presence or absence of BSA-
AGEs on cell proliferation as described in section (2.4.3.11). Cell viability was assessed 
using automated cell counter as mentioned earlier in section (2.4.3.12). In addition, the effect 
of MC extracts in the presence or absence of BSA-AGEs on cell migration was determined 
using the wound-healing assay described in detail in section (2.4.3.13). Cell differentiation 
was assessed using Matrigel™ tube formation assay as described in section (2.4.3.14). MC-
induced signalling pathway was investigated using Western blotting as mentioned in section 




5.4.1 Effects of BSA, BSA-AGEs, MCP, MCF and charantin on BAEC proliferation. 
Effects of different concentrations (10 – 75 µg/mL) of MCP, MCF and charantin extracts 
were studied on BAEC proliferation after a treatment for 72 hours (Figures 5.1-5.5). To 
check the cell response, FGF-2 was used as positive control and induced a significant 
increase in the cell number by 67% (p =0.0252), compared to the untreated control cells 
(Figures 5.1-5.5). The addition of increasing concentrations of MC extracts and charantin 
significantly enhanced BAEC proliferation in a dose-dependent manner, with a peak of 
stimulation at 50 g/mL (Figure 5.1-5.3). Briefly, at 10, 50 and 75 g/mL, MCP increased 
BAEC proliferation of cells by 76% (10 g/mL, p = 0.0240), 125% (50 g/mL, p = 0.0259) 
and 83% (75 g/mL, p = 0.0281), respectively, compared to untreated control cells (Figure 
5.1). At the same concentrations, MCF increased the cell growth by 69% (10 g/mL, p = 
0.0251), 117% (50 g/mL, p = 0.0277) and 81% (75 g/mL, p = 0.0261), compared to the 
control (Figure 5.2). Similarly, charantin increased cell proliferation by 43% (10 g/mL, p = 
0.0254), 103% (50 g/mL, p = 0.0273) and 50% (75 g/mL, p = 0.0197) when compared to 
the control (Figure 5.3). On the contrary, 50 µg/ml BSA-AGEs increase the cell number 
(32%, p =0.0215), while 75 µg/ml BSA-AGEs caused (11%, p = 0.04) inhibition of cell 








Figure 5.1: Effect of different concentrations of MCP extract on BAEC proliferation. 
Bovine aortic endothelial cells (2.5 x 104 / ml) were seeded in 24-well plates and incubated with 
different concentrations of MCP extract (10 – 75 µg/ml) for 72 hours. Fibroblast growth factor-2 (25 








Figure 5.2: Effect of different concentrations of MCF extract on BAEC proliferation. 
Bovine aortic endothelial cells (2.5 x 104 / ml) were seeded in 24-well plates and incubated with 
different concentrations of MCF extract (10 – 75 µg/ml) for 72 hours. Fibroblast growth factor-2 (25 








Figure 5.3: Effect of different concentrations of charantin extract on BAEC 
proliferation. Bovine aortic endothelial cells (2.5 x 104 / ml) were seeded in 24-well plates and 
incubated with different concentrations of charantin extract (10 – 75 µg/ml) for 72 hours. Fibroblast 
growth factor-2 (25 ng/ml) was used as a positive control. Results are presented as mean ± SD (n=3). 







Figure 5.4: Effect of different concentrations of BSA-AGEs on BAEC proliferation. 
Bovine aortic endothelial cells (2.5 x 104 / ml) were seeded in 24-well plates and incubated with 
different concentrations of BSA-AGEs (10 – 75 µg/ml) for 72 hours. Fibroblast growth factor-2 (25 








Figure 5.5: Effect of different concentrations of BSA on BAEC proliferation. Bovine 
aortic endothelial cells (2.5 x 104 / ml) were seeded in 24-well plates and incubated with different 
concentrations of BSA (10 – 75 µg/ml) for 72 hours. Fibroblast growth factor-2 (25 ng/ml) was used 
as a positive control. Results are presented as mean ± SD (n=3).  
5.4.2 Effects of MC and charantin extracts on AGE-induced inhibition of endothelial 
cell proliferation  
BSA-AGEs were studied in the presence or absence of MC and charantin extracts (10 µg/ml) 
on BAEC proliferation using the Coulter counter (Figure 5.6). First, the cell response with the 
pro-angiogenic growth factor FGF-2, the positive control, which significantly increased the 
cell number by 2.2-fold (p = 0.007), compared to the untreated control cells. High 
concentration of BSA-AGEs (250 µg/ml) inhibited cell proliferation by 0.5-fold (p = 0.008) 
when compared to the untreated control cells (Figure 5.6). The addition of MC extracts to 
BSA-AGEs reduced by 1.9-fold (p = 0.0068) the inhibitory effect of BSA-AGEs on the 
proliferation of BAEC treated with the addition of MCP extract and by 1.7-fold (p = 0.009) 
the inhibitory effect of BSA-AGEs on the proliferation of BAEC treated with the addition of 




Figure 5.6: Effects of the MC and charantin extracts on AGE-induced inhibition of 
endothelial cell proliferation. Bovine aortic endothelial cells (2.5 x 104 / ml) were seeded in 24-
well plates and incubated with 10 µg/ml of Momordica charantia extracts and 250 µg/ml BSA-AGEs 
for 72 hours. Fibroblast growth factor-2 (25 ng/ml) was used as a positive control. Results are 
presented as mean ± SD (n=3). ** p < 0.01. 
5.4.3 Effects of BSA, BSA-AGEs, MCP, MCF and charantin on BAEC migration 
(wound-healing assay) 
Since cell migration is an essential process for angiogenesis (Vestweber, 2007), it was 
important to evaluate the effects of BSA-AGEs, BSA, MCP, MCF and charantin on BAEC 
migration using an in vitro denudation injury model such as the wound-healing assay (Figure 
5.7). Representative photomicrographs of cell migration in untreated condition (Figure 5.7, 
A), or treated conditions either with FGF-2 (Figure 5.7, B), BSA-AGEs (Figure 5.7), BSA 
(Figure 5.8), MCP (Figure 5.9), MCF (Figure 5.10) and charantin (Figure 5.11) were shown. 
FGF-2 (25 ng/mL), used as a positive control, significantly increased the distance of cell 
migration by 26.5% (p = 0.0282) and the number of migrated cells by 47% (p = 0.0284), 
when compared to untreated control cells (Figure 5.7, B). BSA-AGEs at a concentration of 
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75 µg/ ml significantly reduced the distance of BAEC migration into the denuded area by 5% 
(p < 0.05). In addition, the number of migrated cells was inhibited by 13% (p < 0.05), 
compared to the control (Figure 5.7). Furthermore, BSA at the same concentration did not 
change the number of migrated cells and 9% reduction of the distance of migration was 
observed, compared to the control (Figure 5.8). At 10 µg/mL, MCP significantly increased 
BAEC migration at a similar level to FGF-2 with an enhancement of the distance of 
migration by 27% (p = 0.0284) and the number of migrated cells by 43% (p = 0.0284) when 
compared to untreated control cells. MCP increased the distance of migration significantly by 
16.7% (50 µg/ml, p = 0.0289) and 11.8% (75 µg/ml, p = 0.0282). MCP increased the number 
of migrated cells by 33% (50 µg/ml, p = 0.0288) and decreased 14% (75 µg/ml, p = 0.0229), 
respectively (Figure 5.9). At the concentration of 50 µg/ ml, MCF (Figure 5.10) and charantin 
(Figure 5.11) significantly increased the migrated cell number by 45% (50 µg/ml, p = 0.0281) 
and 40% (50 µg/ml, p = 0.0286), respectively. Furthermore, MCF at the concentration of 75 
µg/ ml increased the distance of migration by 22% (75 µg/ ml, p = 0.0292), while charantin at 
the concentration of 10 µg/ ml increased the distance of migration by 18% (10 µg/ ml, p = 
0.0277). Briefly, a significant decrease of the migrated cell number was observed by 7% (p = 
0.0313) by the addition of 10 µg/ ml MCF, then to reach a peak of 45% (p = 0.0281) at 50 
µg/ ml, compared to the control (Figure 5.10). The number of migrated cells slightly 
increased by 25% (p = 0.0295) in the presence of 75 µg/ ml MCF (Figure 5.10). At all 
concentrations used, charantin increased the number of migrated cells reaching a peak of 45% 










Figure 5.7: Representative photomicrographs and bar graph showing the effects of 
BSA-AGEs on BAEC migration using wound-healing assay. (a) A representative 
photomicrographs shows the effect of (A) Control (B) FGF-2 (25ng /ml) (C) BSA-AGE (10 µg/ml) 
(D) BSA-AGE (50 µg/ml) (E) BSA-AGE (75 µg/ml) for 24 hours. The numbers of migrated cells in 
the denuded area were counted (original magnification X40, scale bar = 100 µm). Experiments were 
performed in triplicate wells and repeated three times. A representative example is shown. (b) The bar 








Figure 5.8: Representative photomicrographs and bar graph showing the effects of BSA 
on BAEC migration using wound-healing assay. (a) A representative photomicrographs 
shows the effect of (A) Control, (B) FGF-2 (25ng /ml), (C) BSA (10 µg/ml), (D) BSA (50 µg/ml) and 
(E) BSA (75 µg/ml) for 24 hours. The numbers of migrated cells in the denuded area were counted 
(original magnification X40, scale bar = 100 µm). Experiments were performed in triplicate wells and 
repeated three times. A representative example is shown. (b) The bar graph shows the effects of BSA 







Figure 5.9: Representative photomicrographs and bar graph showing the effects of 
MCP on BAEC migration using wound-healing assay. (a) A representative 
photomicrographs shows the effect of (A) Control (B) FGF-2 (25ng /ml) (C) MCP (10 µg/ml) (D) 
MCP (50 µg/ml) (E) MCP (75 µg/ml) for 24 hours. The numbers of migrated cells in the denuded 
area were counted (original magnification X40, scale bar = 100 µm). Experiments were performed in 
triplicate wells and repeated three times. A representative example is shown. (b) The bar graph shows 







Figure 5.10: Representative photomicrographs and bar graph showing the effects of 
MCF on BAEC migration using wound healing assay. (a) A representative 
photomicrographs shows the effect of (A) Control, (B) FGF-2 (25ng /ml), (C) MCF (10 µg/ml), (D) 
MCF (50 µg/ml) and (E) MCF (75 µg/ml) for 24 hours. The numbers of migrated cells in the denuded 
area were counted (original magnification X40, scale bar = 100 µm). Experiments were performed in 
triplicate wells and repeated three times. A representative example is shown. (b) The bar graph shows 







Figure 5.11: Representative photomicrographs and bar graph showing the effects of 
charantin on BAEC migration using wound healing assay. (a) A representative 
photomicrographs shows the effect of (A) Control, (B) FGF-2 (25ng /ml), (C) charantin (10 µg/ml), 
(D) charantin (50 µg/ml) and (E) charantin (75 µg/ml) for 24 hours. The numbers of migrated cells in 
the denuded area were counted (original magnification X40, scale bar = 100 µm). Experiments were 
performed in triplicate wells and repeated three times. A representative example is shown. (b) The bar 
graph shows the effects of charantin on BAEC migration. Graph shows the mean ± S.D. * p < 0.05 
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5.4.4 Effect of MC and charantin extracts on AGE-induced inhibition of endothelial cell 
migration using wound-healing assay 
To assess the effect of high concentration of BSA-AGEs (250 µg/ml) on the migration of 
BAEC, the cells were subjected to a wound-healing assay followed by a 24-hour treatment in 
the presence or absence of 10 µg/mL MCP, MCF extracts and charantin (Figure 5.12, a). 
Representative photomicrographs of cell migration in untreated condition (Figure 5.12, A), or 
treated conditions either with FGF-2 (Figure 5.12, B), BSA-AGEs (Figure 5.12, C) or BSA-
AGEs combined with MCP (Figure 5.12, D), MCF (Figure 5.12, E) or with charantin (Figure 
5.12, F) were shown. FGF-2, used as a positive control, significantly increased the distance of 
cell migration by 1.37-fold (p = 0.031) and the number of migrated cells by 1.5-fold (p = 
0.028), compared to untreated control cells. The cell treatment with high concentration of 
BSA-AGEs decreased the cell migration by 0.5-fold (p = 0.028) the distance of migration and 
by 0.58-fold (p = 0.026) the number of migrated cells. The addition of MCP extract to high 
concentration of BSA-AGEs reduced the inhibitory effect of BSA-AGEs on BAEC migration 
by about 1.45-fold (p = 0.03) the distance of migration and by about 1.6-fold (p = 0.028) the 
number of migrated cells, compared to BSA-AGEs treated cells. MCF extracts reduced the 
inhibitory effect of BSA-AGEs on cells by 1.67-fold (p = 0.029) the distance of migration 
and by 1.64-fold (p = 0.029) the number of migrated cells. Charantin was also reduce the 
inhibitory effect of BSA-AGEs by 1.28-fold (p = 0.035) the distance of migration and by 











Figure 5.12: Representative Photomicrographs and bar graph showing the effects of 
MC and charantin extracts on AGE-induced inhibition of endothelial cell migration. (a) 
A representative photomicrographs shows the effect of (A) control, (B) FGF-2 (25 ng /ml), (C) 
BSA-AGEs at 250 µg/ml, (D) BSA-AGEs combined with 10 µg/ml MCP, (E) BSA-AGEs combined 
with 10 µg/ml MCF and (F) BSA-AGEs combined with 10 µg/ml charantin, for 24 hours incubation. 
The numbers of migrated cells in the denuded area were counted and the distance of migration 
measured using image J software (original magnification, 40X, scale bar = 100 µm). Experiments 
were performed in triplicate and repeated three times. (b) The graph shows the effects of combination 
of BSA-AGEs (250 µg/ml) with Momordica charantia extracts on BAEC migration. The bar graph 
shows the mean ± S.D. * p < 0.05. 
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5.4.5 Effects of BSA, BSA-AGEs, MCP. MCF and charantin on BAEC cell viability 
using automated cell counter  
Figure 5.13 shows no cytotoxic effect of BSA-AGEs when used at 10 and 50 g/ml, while a 
significant (p =0.00002) cytotoxic effect causing 28% decrease of cell viability was detected 
by the presence of 75 g/ml BSA-AGEs, compared to the untreated control cells, after 72 
hours incubation (Figure 5.14). In addition, all MCP, MCF and charantin extracts had no 
cytotoxic effect on BAEC (Figures 5.15, 5.16, 5.17). 
 
Figure 5.13: Effect of BSA-AGEs on BAEC viability using trypan blue assay. Bovine 
aortic endothelial cells (2.5 x 104 / ml) were seeded in 24-well plates and incubated with different 
concentrations of BSA-AGEs (10 – 75 μg/ml). After 72 hours incubation, the cell suspension (10 μl) 
was mixed with trypan blue dye (10 μl) and cell viability was assessed by automated cell counter. 








Figure 5.14: Effect of BSA on BAEC viability using trypan blue assay. Bovine aortic 
endothelial cells (2.5 x 104 / ml) were seeded in 24-well plates and incubated with different 
concentrations of BSA (10 – 75 μg/ml). After 72 hours incubation, the cell suspension (10 μl) was 
mixed with trypan blue dye (10 μl) and cell viability was assessed by automated cell counter. Results 










Figure 5.15: Effect of MCP on BAEC viability using trypan blue assay. Bovine aortic 
endothelial cells (2.5 x 104 / ml) were seeded in 24-well plates and incubated with different 
concentrations of MCP (10 – 75 μg/ml). After 72 hours incubation, the cell suspension (10 μl) was 
mixed with trypan blue dye (10 μl) and cell viability was assessed by automated cell counter. Results 









Figure 5.16: Effect of MCF on BAEC viability using trypan blue assay. Bovine aortic 
endothelial cells (2.5 x 104 / ml) were seeded in 24-well plates and incubated with different 
concentrations of MCF (10 – 75 μg/ml). After 72 hours incubation, the cell suspension (10 μl) was 
mixed with trypan blue dye (10 μl) and cell viability was assessed by automated cell counter. Results 










Figure 5.17: Effect of charantin on BAEC viability using trypan blue assay. Bovine aortic 
endothelial cells (2.5 x 104 / ml) were seeded in 24-well plates and incubated with different 
concentrations of charantin (10 – 75 μg/ml). After 72 hours incubation, the cell suspension (10 μl) 
was mixed with trypan blue dye (10 μl) and cell viability was assessed by automated cell counter. 
Results are expressed as mean ± SD (n = 3) of three independent experiments. 
 
5.4.6 Effects of BSA, BSA-AGEs, MCP, MCF and charantin on BAEC differentiation 
using tri-dimensional Matrigel TM culture 
Within 24 hours incubation, activated endothelial cells differentiated, aligned to form tubes 
organized in a capillary-like network (Figure 5.18, a). Representative photomicrographs of 
cell differentiation/ tube formation in untreated condition (Figure 5.18, A), or treated 
conditions either with FGF-2 (Figure 5.18, B), or 10 µg/ml (Figure 5.18, C), 50 µg/ml 
(Figure 5.18, D), and 75 µg/ml (Figure 5.18, E), of BSA-AGEs (Figure 5.18), BSA (Figure 
5.19), MCP ( Figure 5.20), MCF (Figure 5.21) or of charantin (Figure 5.22) were shown. 
Treated with FGF-2 (Figure 5.18, B), the positive control, the stimulated cells formed a 
capillary-like network with a significant increase of the network density by 42% (p = 0.0058) 
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compared to the untreated control cells which formed a few tube-like structures (Figure 5.18, 
A). At 10 and 50 µg/ml, BSA-AGEs significantly (p ˂ 0.01) increased tube formation by 
119% and 169%, respectively, while at 75 µg/ml, the tube formation was significantly (p = 
0.012) inhibited by 14% of control, compared to the untreated control cells (Figure 5.18). 
BSA at the same concentration showed no effect on tube formation compared to untreated 
cells (Figure 5.19). While no effect was noticed at the lowest concentration of MCP, in the 
presence of 50 and 75 µg/ml MCP, the tube formation significantly increased by 74% ( p = 
0.0093) and 42% (p = 0.0086), respectively, compared to the control (Figure 5.20). At all 
concentrations used, MCF significantly enhanced tube formation by 162% (p = 0.0082) at 10 
µg/ml, 197% (p = 0.0078) at 50 µg/ml and 182% (p = 0.0079) at 75 µg/ml, compared to the 
control (Figure 5.21). In addition, charantin significantly enhanced endothelial tube formation 
with increased concentrations (Figure 5.22). Indeed, charantin significantly increased the 
number of closed areas by 57% (p = 0.0096) at 10 µg/ml, by 149% (p = 0.0076) at 50 µg/ml 















Figure 5.18: Effect of BSA-AGE on BAEC tube formation assay. (a) Representative 
photomicrographs showing the effect of (A) control, (B) FGF2 (25 ng/ml), (C) AGE (10 µg/ml), (D) 
AGE (50 µg/ml) and (E) AGE (75 µg/ml) on BAEC differentiation (original magnification, 40X).  (b) 
The graph shows the effects of BSA-AGEs on BAEC tube formation. The bar graph shows the mean 







Figure 5.19: Effect of BSA on BAEC tube formation assay. (a) Representative 
photomicrographs showing the effect of (A) control, (B) FGF2 (25 ng/ml), (C) BSA (10 µg/ml), (D) 
BSA (50 µg/ml) and (E) BSA (75 µg/ml) on BAEC differentiation (original magnification, 40X).  (b) 
The graph shows the effects of BSA on BAEC tube formation. The bar graph shows the mean ± S.D. 







Figure 5.20: Effect of MCP on BAEC tube formation assay. (a) Representative 
photomicrographs showing the effect of (A) control, (B) FGF2 (25 ng/ml), (C) MCP (10 µg/ml), (D) 
MCP (50 µg/ml) and (E) MCP (75 µg/ml) on BAEC differentiation (original magnification, 40X).  (b) 
The graph shows the effects of MCP on BAEC tube formation. The bar graph shows the mean ± S.D. 







Figure 5.21: Effect of MCF on BAEC tube formation assay. (a) Representative 
photomicrographs showing the effect of (A) control, (B) FGF2 (25 ng/ml), (C) MCF (10 µg/ml), (D) 
MCF (50 µg/ml) and (E) MCF (75 µg/ml) on BAEC differentiation (original magnification, 40X).  (b) 
The graph shows the effects of MCF on BAEC tube formation. The bar graph shows the mean ± S.D. 







Figure 5.22: Effect of charantin on BAEC tube formation assay. (a) Representative 
photomicrographs showing the effect of (A) control, (B) FGF2 (25 ng/ml), (C) charantin (10 µg/ml), 
(D) charantin (50 µg/ml) and (E) charantin (75 µg/ml) on BAEC differentiation (original 
magnification, 40X).  (b) The graph shows the effects of charantin on BAEC tube formation. The bar 
graph shows the mean ± S.D. **p < 0.01. 
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5.4.7 Effect of MC and charantin extracts on AGE-induced inhibition of endothelial cell 
tube formation using tri-dimensional Matrigel TM culture 
Endothelial cell differentiation assessed by the tube formation assay was analysed using a 3-
D MatrigelTM culture. Within 24 hours of incubation, activated endothelial cells differentiation, 
aligned to form tubes organized in a capillary-like network (Figure 5.23. a). Representative 
photomicrographs of tube formation in untreated condition (Figure 5.23, A), or treated 
conditions either with FGF-2 (Figure 5.23, B), BSA-AGEs (Figure 5.23, C), or BSA-AGEs 
combined with MCP (Figure 5.23, D), MCF (Figure 5.23, E) or with charantin (Figure 5.23, 
F) were shown. Treated with FGF-2, the positive control, the stimulated cells formed a 
capillary-like network with a significant increase of the network density by 2.0-fold (p = 
0.001), compared to the untreated control cells which formed a few tube-like structures 
(Figure 5.23, B). High concentration of BSA-AGEs significantly decreased the tube 
formation by 0.67-fold (p = 0.014), while native BSA had no effect, compared to the control 
(Figure 5.23, C). The addition of MC extracts (MCP and MCF) to high concentration BSA-
AGEs not only counteracted the inhibitory effect of BSA-AGEs on BAEC tube formation but 
also significantly increased the tube formation by 2.7-fold (p < 0.01), compared to the BSA-
AGEs treated cells (Figure 5.23, D and 5.23, E). Charantin reduced the inhibitory effect of 
BSA-AGEs on tube formation and increased the tubulogenesis process by 1.5-fold (p = 












Figure 5.23: Effect of MC and charantin extracts on AGE-induced inhibition of 
endothelial cell tube formation. (a) Representative photomicrographs showing the effect of (A) 
control, (B) FGF2 (25 ng/ml), (C) AGE (250 µg/ml), (D)  AGE (250 µg/ml) + MCP (10 µg/ml), (E) 
AGE (250 µg/ml) + MCF (10 µg/ml) and (F) AGE (250 µg/ml) + charantin (10 µg/ml) on BAEC 
differentiation (40 x). (b) The bar graph shows the effects of AGE (250 µg/ml) combined with 
Momordica charantia extracts (10 µg/ml), FGF-2 (25ng /ml) on BAEC tube formation after 24 hours. 
The number of closed areas was counted. The bar graph shows the mean ± S.D. (*) and (**) signify a 
statistically significant difference (p ˂ 0.05 and p ˂ 0.01) compared with the AGE .Experiments were 
performed in triplicate wells and repeated at least three times. A representative example is shown. 
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5.4.8 Effect of Momordica charantia extracts on extracellular signal-regulated kinase 1/2 
phosphorylation in BAEC. 
Since activating ERK1/2 is the key step of angiogenesis (Baek et al., 2012), in this regards, p-
ERK1/2 expression in presence of Momordica charantia extracts was examined. To optimize 
the incubation time corresponding to the maximal cell signalling induced by MC extracts, 
Western blotting was used to determine the expression of p-ERK1/2 in BAEC treated with 10 
µg/mL MCP for 10 minutes and 1-3-6 hours incubation along with cells treated with FGF-2 
for 10 minutes incubation (Figure 5.24). At 10 minutes incubation, the cell treatment with 
MCP significantly increased the phosphorylation of ERK1/2 like FGF-2, compared to the 
basal level of p-ERK1/2 expressed in untreated control cells. The expression of p-ERK1/2 
slightly decreased at 1 hour incubation point, and nearly disappeared at 6 hours incubation 
point (Figure 5.24).  
The phosphorylation of ERK was initiated by exogenous addition of different concentrations 
(10-75 µg/ml) of MC extract and 25 ng/mL FGF-2 for 10-minute. BAEC proteins lysates 
were subjected to western blotting analysis. As expected, FGF-2 significantly induced p-
ERK1/2 over-expression by 5.5-fold increase of p-ERK2 and by 1.9-fold increase of p-
ERK1, compared to the basal level of p-ERK1/2 expressed in untreated control cells. The 
addition of 50 µg/ml of MCP extract (Figure 5.25) significantly (p =0.0075) increased p-
ERK1/2 over-expression by 4.7-fold increase of p-ERK2 and by 1.8-fold increase of p-
ERK1, compared to the control. At the same concentration, MCF significantly (p =0.0073) 
induced p-ERK1/2 over-expression by 4.5-fold increase p-ERK2 and by 1.8-fold p-ERK1, 
compared to the control (Figure 5.26). At the same conditions, charantin significantly 
increased p-ERK1/2 expression by 3.79-fold (p =0.0075) p-ERK2 and by 1.23-fold p-ERK1, 







Figure 5.24: Effect of MCP on P-ERK expression in different time. (a) A representative 
Western blot showing the up regulation of ERK1 / ERK2 phosphorylation by MCP (10 µg/ml) and 
FGF2 in different time. (b) The bar graph shows the effects of control, FGF2 (25 ng/ml) and MCP (10 
µg/ml) in different time (10 minutes, 1 hour, 3 hours and 6 hours). The results expressed are relative 
to total-ERK1/2 expression. To check the equal loading of proteins, total-ERK1/2 was used as loading 
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Figure 5.25: Effect of different concentration of MCP on P-ERK expression in 10 
minutes. (a) A representative Western blot showing the up regulation of ERK1 / ERK2 
phosphorylation by MCP at different concentration (10, 50, 75 µg/ml) in 10 minutes time. (b) The bar 
graph shows the effects of control, FGF2 (25 ng/ml), MCP (10 µg/ml), MCP (50 µg/ml) and MCP (75 
µg/ml) in 10 minutes. The results expressed are relative to total-ERK1/2 expression in control. To 
check the equal loading of proteins, total-ERK1/2 was used as loading control. Each panel was 
representative of at least three independent experiments. (**) signify a statistically significant 








Figure 5.26: Effect of different concentration of MCF on P-ERK expression in 10 
minutes. (a) A representative Western blot showing the up regulation of ERK1 / ERK2 
phosphorylation by MCF at different concentration (10, 50, 75 µg/ml) in 10 minutes time. (b) The bar 
graph shows the effects of control, FGF2 (25 ng/ml), MCF (10 µg/ml), MCF (50 µg/ml) and MCF (75 
µg/ml) in 10 minutes. The results are expressed as relative to total-ERK1/2 expression. To check the 
equal loading of proteins, total-ERK1/2 was used as loading control. Each panel was representative of 
at least three independent experiments. (**) signify a statistically significant difference (p ˂ 0.01) 








Figure 5.27: The effect of different concentration of charantin on P-ERK expression in 
10 minutes. (a) A representative Western blot showing the up regulation of ERK1 / ERK2 
phosphorylation by charantin at different concentration (10, 50, 75 µg/ml) in 10 minutes time. (b) The 
bar graph shows the effects of control, FGF2 (25 ng/ml), charantin (10 µg/ml), charantin (50 µg/ml) 
and charantin (75 µg/ml) in 10 minutes. The bands and the results are expressed as relative to total-
ERK1/2 expression. To check the equal loading of proteins, total-ERK1/2 was used as loading 
control. Each panel was representative of at least three independent experiments. (**) signify a 
statistically significant difference (p ˂ 0.01) compared with the control. 
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5.4.10 Effects of AGEs or Momordica charantia extracts on cell differentiation after 
RAGE neutralization 
To understand cellular mechanisms whereby either the Momordica charantia extracts or AGE 
can activate ERK via the receptor of AGEs (RAGE). In this regards, Figure 5.28 shows the 
effect of MC extracts or AGE on BAEC tube formation when (RAGE) neutralized by RAGE 
antibody. Isotybic control (IgG) was used as positive control. All extracts and AGE combined 
with IgG were significantly (p < 0.05) increased tube formation compared to untreated cells 
(control). Furthermore, cells were treated with RAGE (20 µg/ml) showed significant (p < 
0.05) reduction on tube formation compared with control group. AGE showed a significant 
inhibition on BAEC tube formation (treated with RAGE) by 92% of control. In addition, 
MCP, MCF and charantin were showed a significant (p < 0.05) inhibition on tube formation 
by 94%, 93% and 95% of control respectively when cells were neutralized with RAGE 




















Figure 5.28: Effects of AGEs or Momordica charantia extracts on cell differentiation 
assay after RAGE neutralization. (a) Representative photomicrographs showing the effect of (A) 
AGE (10 µg/ml), (B) IgG + AGE and (C) RAGE + AGE. (b) Representative photomicrographs 
showing the effect of (A) MCP (10 µg/ml), (B) IgG + MCP and (C) RAGE + MCP. (c) 
Representative photomicrographs showing the effect of (A) MCF (10 µg/ml), (B) IgG + MCF and (C) 
RAGE + MCF. (d) Representative photomicrographs showing the effect of (A) charantin (10 µg/ml), 
(B) IgG + charantin and (C) RAGE + charantin on BAEC differentiation (40 x). (e) The bar graph 
shows the effects of all conditions (10μg /ml) ± IgG and RAGE Ab on BAEC tube formation after 24 
hours. The number of closed areas was counted. The bar graph shows the mean ± S.D. (*) signify a 
statistically significant difference (p ˂ 0.05) compared with the control. Experiments were performed 




5.4.11 Effects of AGEs or Momordica charantia extracts on extracellular signal-
regulated kinase 1/2 phosphorylation in BAEC after RAGE neutralization 
ERK1/2 protein activity characterized as its phosphorylated form is required for EC 
Proliferation, migration and tube formation in angiogenesis (Slevin et al., 2002). To 
demonstrate whether MCP, MCF extracts and charantin acted through the receptor for AGEs 
(RAGE) in the induction of the signal transduction, the cells were treated with anti-RAGE 
antibody to neutralize the action of the receptors before being stimulated for 10 minutes 
incubation with 50 µg/ml BSA-AGEs or with 10 µg/ml MC extracts and charantin (Figure 
5.30). First, using the isotype control of anti-RAGE antibody, a significant induction of p-
ERK1/2 overexpression was observed by the addition of BSA-AGEs, MC extracts and 
charantin, compared to the basal level of p-ERK1/2 expression in untreated control cells 
(Figure 5.31). By neutralizing RAGE with anti-RAGE antibody, a significant decrease of 
BSA-AGE-induced p-ERK1/2 overexpression was observed as expected but also a strong 
inhibition of p-ERK1/2 overexpression induced by MC extracts and charantin, compared to 














Figure 5.29: Effect of AGE, MCP, MCF and charantin on P-ERK expression in 10 
minutes. (a) A representative Western blot showing the up regulation of ERK1 / ERK2 
phosphorylation by AGE (50 µg/ml) and MC extracts at the concentration of (10 µg/ml) in 10 minutes 
time. (b) The bar graph shows the effects of control, AGE (50 µg/ml), MCP (10 µg/ml), MCF (10 
µg/ml) and charantin (10 µg/ml) in 10 minutes. The results are expressed as relative to total-ERK1/2 
expression. To check the equal loading of proteins, total-ERK1/2 was used as loading control. Each 
graph was representative of at least three independent experiments. (**) signify a statistically 







Figure 5.30: The effect of AGE, MCP, MCF and charantin on P-ERK expression in 10 
minutes with RAGE Ab. (a) A representative Western blot showing the down regulation of ERK1 
/ ERK2 phosphorylation by AGE (50 µg/ml) and MC extracts at the concentration of (10 µg/ml) in 
the presence of RAGE (20 µg/ml). (b) The bar graph shows the effects of control, RAGE (20 µg/ml), 
AGE (50 µg/ml), MCP (10 µg/ml), MCF (10 µg/ml) and charantin (10 µg/ml) in the presence of 
RAGE (20 µg/ml) for 10 minutes. The results are expressed as relative to total-ERK1/2 expression. 
To check the equal loading of proteins, total-ERK1/2 was used as loading control. Each graph was 
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Figure 5.31: The effect of AGE, MCP, MCF and charantin on P-ERK expression in 10 
minutes with IgG. (a) A representative Western blot showing the up regulation of ERK1 / ERK2 
phosphorylation by AGE (50 µg/ml) and MC extracts at the concentration of (10 µg/ml) in the 
presence of IgG (20 µg/ml). (b) The bar graph shows the effects of control, IgG (20 µg/ml), AGE (50 
µg/ml), MCP (10 µg/ml), MCF (10 µg/ml) and charantin (10 µg/ml) in the presence of IgG (20 
µg/ml) for 10 minutes. The results are expressed as relative to total-ERK1/2 expression. To check the 
equal loading of proteins, total-ERK1/2 was used as loading control. Each graph was representative of 
at least three independent experiments. (**) signify a statistically significant difference (p ˂ 0.01) 
compared with the control. 
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5.5 Discussion  
Initial development of complications in diabetes like disturbed wound healing, neuropathy, 
retinopathy and nephropathy have been found to be linked with reduced angiogenesis 
(Ahmed et al., 2008). Studies have determined that migration of endothelial cells 
proliferation and formation of capillary tube in vitro is decreased by hyperglycemia and 
thereby leads to inadequate angiogenesis (Martin et al., 2003). There are several in vivo and 
in vitro experiments whose findings provide strong evidence about the development of 
diabetic complications can caused by accumulation of AGEs, which are formed in diabetic 
patients due to chronic hyperglycemia (Giardino et al., 1994; Goh and Cooper, 2008; 
Vlassara and Palace, 2002; Yamagishi, 2011; Zheng et al., 2002). Consequently, it has been 
hypothesized that a significant role in angiogenesis is played by protein glycation, through 
AGE synthesis (Okamoto et al., 2002; Stitt et al., 2005). BSA-AGEs have been used as 
glycated proteins in the current study at concentrations between 10 μg/ml and 75 μg/ml. The 
concentration range 10-50 μg/ml was selected since Xu et al. (2003) have reported that it may 
represent the lowest level of plasma AGEs found in patients suffering from diabetes. 
Moreover, the 75 μg/ml concentration was used to verify the findings of Chibber et al. (1997) 
which showed that BSA-AGE demonstrates toxicity to BAEC only when its concentration 
exceeds 62.5 µg/ml. In the present study, BSA-AGE was unable to demonstrate any cytotoxic 
effect on BAECs when used at concentrations of 10-50 μg/ml; however, significantly 
optimum increase in cell proliferation, migration and tube formation was caused when 
concentration of BSA-AGEs was 50 μg/ml i.e. a concentration comparable to the diabetic 
situation in vivo (Chen et al., 2009). In addition to these, it was found that BSA-AGEs at high 
concentrations i.e. 75 μg/ml caused inhibition of cell proliferation, migration and tube 
formation, this finding is supported by previous research (Chibber et al., 1997). Besides this, 
BSA-AGEs have also been employed for exploring the influence of protein glycation on 
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various cell lines and tissues (Franke et al., 2009; Hirasawa et al., 2011; Hung et al., 2010; 
Kowluru, 2005). However, BAECs remained unaffected by unglycated BSA.  
This study indicated that all MC extracts (MCF, MCP and charantin) increased endothelial 
cell proliferation in a dose-response curve. Compared to FGF-2, the lowest and the highest 
concentrations of MCP and MCF used (i.e. 10 and 75 µg/ml) stimulated cell proliferation 
reaching the same level than the cell proliferation induced by FGF-2 while a peak of 
stimulation (higher than FGF-2 effect) was reached by the presence of the intermediary 
concentration of MC extracts (i.e. 50 µg/ml). The bell-shaped curve is indicative of a bivalent 
bridging mechanism describing the cell response (i.e. cell proliferation, migration and tube 
formation) induced by the activation of signal transduction pathways through the 
dimerization/oligomerization of specific cell-surface receptors after binding with the ligand 
(Posner et al, 1998). The maximal cell response was obtained with 50 µg/ml of all the 
extracts, which seem to correspond to the optimal oligomerisation of the receptors to induce 
the maximal activation of the signalling pathways. Among the photochemical components 
and proteins previously mentioned, MC extracts contain insulin-like proteins that can 
stimulate endothelial cell proliferation by acting as an insulin-like growth factor (a pro-
angiogenic growth factor) bound to two dimers of insulin receptors followed by the activation 
of the receptor tyrosine kinase. In addition, a recent study has reported that topical insulin 
accelerates the skin wound healing in diabetic rats (Lima et al, 2012). A bell-shaped curve 
was also observed in response to the mitogenic effect of charantin, which is only composed 
of the combination of sterol and glucose metabolites. The pro-mitogenic activity of charantin 
on endothelial cells showed lower effect than FGF-2 at the lowest and highest concentrations 
of charantin while the maximum stimulation (higher than FGF-2 effect) was reached in the 
presence of 50 µg/ml charantin. On hydrolysis, charantin gives glucose and a sterol. Glucose 
is essential, and a vital metabolite for the cell function and its facilitated transport through the 
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hexose transport (e.g. GLUT1) cannot explain the bell-shaped curve that describes a receptor-
dependent mechanism (Young et al, 2011). Therefore, the charantin, which can be considered 
as a glycated phytochemical, could be recognized by a receptor for AGEs, for example. 
Altogether, these findings suggest that MC extracts and charantin stimulated endothelial cell 
proliferation through dimerization/oligomerisation of receptors which remain to be identified.  
Using the wound-healing assay, this study showed that MC extracts increased endothelial cell 
migration in a dose-dependent manner. Charantin effect can be justified by the presence of 
sterol (its hydrolytic metabolite) which induces changes in the contents of membrane 
cholesterol and alters the micro-viscosity of the plasma membrane, which in turn can regulate 
endothelial cell migration. These findings suggest that the pro-migratory effects of MC 
extracts and charantin occurred through a receptor-dependent mechanism and plasma 
membrane physico-chemical changes.  
Tube formation results suggest that MCF extracts contain more insulin-like proteins or other 
stimulating agents than MCP extracts. In contrast to MCP and MCF extracts, charantin 
increased tube formation with its concentrations: starting with a stimulatory effect similar 
than FGF-2 to mostly doubled FGF-2 effect at the highest concentration.  
ERK extracellular signal-regulated kinase 1/2 phosphorylation was studied to comprehend 
the molecular mechanisms behind the action of MC extracts. All of the MC extracts have 
demonstrated a considerable stimulation on ERK1/2. This finding is supported by other 
research studies and verifies the pro-angiogenesis action of MC extracts (Ahmed et al., 1998; 
Teoh et al., 2009). Moreover, it has been established that AGEs interact with RAGE causing 
cell death in the presence of reactive oxygen species (Morita et al., 2013). Whereas, 
stimulation of ERK1/2 by MC still needs to be deciphered. The current study proposes for the 
first time that MC caused activation of ERK1/2 signalling through RAGE, and when RAGE 
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was made ineffective by using anti-RAGE antibodies, tube formation was not observed in 








Chapter 6. General discussion  
6.1 Novel results 
Several important novel results have emerged from this study. MCP, MCF and charantin 
extracts shows antioxidants properties and antiglycation effect on methylglyoxal-derived 
AGE formation.  Furthermore, MC extracts shows a pro-angiogenic effects on endothelial 
cell proliferation, migration and differentiation (tube formation) in BAEC. In addition, MC 
extracts reduce advanced glycation end-products mediated anti-angiogenic effects in vitro. 
This study shows for the first time that MC extracts induced ERK pathway via RAGE.  
6.2 General discussion 
Protein glycation in diabetes cause protein modifications, including structural and functional 
impairments and formation of intra- and inter-protein cross-linking resulting in AGE 
accumulation (Wu et al., 2009). The accumulation of cross-linked AGEs in plasma and 
tissues is thought to account for the long-term risks associated with diabetes and aging 
(Nishigaki et al., 2008). In addition, glycation plays an important role in the pathogenesis of 
microvascular and macrovascular complications of diabetes (Chen et al., 2012). Many 
researchers have emphasized the advantages of using medicinal plants to reduce AGE 
formation by their antioxidants activities and may therefore provide protection to alleviate the 
development of such diabetes-related complications (Tsuji-Naito et al., 2009; Wu et al., 
2009).  
The antioxidant as well as radical-scavenging properties of phenolic compounds tends to be 
generally due to their phenolic hydroxylic groups (Raman and Lau, 1996). The particular free 
radical-scavenging capacity associated with MC extracts could be caused by their 
polyphenolic compounds, including flavonoids, flavonols and other phenolics. Several 
studies have suggested the relation between free radicals-scavenging activity involving 
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polyphenol substances and their own chemical structure (Aksoy et al., 2013; Samak et al., 
2009). In addition, MC has antioxidant activities probably due to the presence of different 
contents of vitamins such as ascorbic acid (Vitamin C), Vitamin A and Vitamin E (Ullah, 
2011; Senthilkumar, 2012).  
 
Important novel findings have emerged from glycation study, which is discussed in relation 
to the published literature mentioned in the previous chapters. In this study, it was established 
for the first time that MCP, MCF extracts and charantin displayed potent inhibitory effects on 
AGE formation in a dose-dependent manner. Previous research has shown that MC extracts 
cause a reduction in serum glucose levels and improve glucose tolerance in normal and 
diabetic humans and animals by increasing insulin sensitivity but without increasing blood 
insulin levels (Raman and Lau, 1996). Furthermore, the higher amount of phenolic 
compounds and flavonoids in all extracts may prevent the formation of AGEs. The AGE 
formation pathway is complex, to understand the inhibition pathway of AGE formation 
induced by MC extracts, more investigations are needed. In addition, numerous researches 
have established that MC dose comprises of several amino acids that could decrease the 
generation of AGEs by the blockage of carbonyl groups (Huang et al., 1999; Yuwai et al., 
1991)  
Certainly, to verify the inhibitory outcome of different MC extracts on AGEs, effect of MC 
on CML contents was investigated. Carboxymethyllysine is one of the most attribute AGE 
products via glycation and oxidation reactions (Fujiwara et al., 2011). Additionally, 
throughout diabetes, elevated degrees of CML contents have been discovered within the 
animal along with human tissues (Dyer et al., 1993; Kamata et al., 2009). These studies 
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confirm that all extracts show inhibitory effect on CML formation. MCF was also having the 
most potent inhibitory effect.  
AGEs have been implicated in the pathogenesis of diabetic complications including vascular 
complications arising from angiogenesis. Notably, excessive angiogenesis may play an 
essential role in diabetic retinopathy and nephropathy, whilst reduced angiogenesis contribute 
to impaired wound-healing (Martin et al., 2003). Specifically, high serum levels of AGEs in 
diabetics are thought to reduce the formation of granulation tissue during wound-healing 
(Teixeira et al., 1999). The results of the current study indicate that high concentrations of 
AGEs reduce BAEC proliferation, migration and tube formation, which are believed to play a 
crucial role in the inhibition of angiogenesis in diabetes. Furthermore, AGE formation may 
cause changes in biological activities of macrophages (Liu et al., 1999), smooth muscle cells 
and fibroblasts (Okano et al., 2002), which are also involved in angiogenesis. On the other 
hand, MC extracts induced BAEC proliferation, migration and tube formation (Pro-
angiogenic activities) which are believed to facilitate the healing of ulcers caused by 
diabetes-induced atherosclerosis of small arteries. These results were supported by previous 
studies (Prasad et al., 2006; Prashanthi et al., 2012). Moreover, in this connection, pro-
angiogenic action of MC was explored for the first time in the presence of high concentration 
of AGEs. The mechanism behind this activity still needs to be explored. AGE/RAGE axis 
and oxidative stress cause abnormal angiogenesis in wound healing (Chen et al., 2012). ERK 
extracellular signal-regulated kinase 1/2 phosphorylation was studied to investigate the 
molecular mechanisms behind the action of MC extracts. All of the MC extracts have 
demonstrated a considerable stimulation of phospho-ERK 1/2 expression. This finding is 
supported by other research studies and verifies the pro-angiogenesis action of MC extracts 
(Ahmed et al., 1998; Teoh et al., 2009). Moreover, it has been established that high 
concentrations of AGEs interact with RAGE causing programmed cell death (apoptosis) with 
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the involvement of reactive oxygen species (Morita et al., 2013). In addition, stimulation of 
phospho-ERK1/2 expression through RAGE by MC needs more investigations. The current 
study proposes for the first time that MC caused activation of ERK1/2 signalling via RAGE. 
Indeed, after RAGE neutralization using specific antibodies, tube formation was not observed 
when cells were stimulated by all extracts in comparison to the control. MC extracts and 
charantin were shown to increase phospho-ERK1/2 expression through RAGE. 
6.3 Conclusion 
The present results have demonstrated that different MC extracts and charantin can 
effectively provide protection against methylglyoxal-derived AGE formation in vitro. This 
finding suggests that the daily consumption of MC extracts is considered to be of potential 
benefit for the prevention of ageing and lifestyle-related diseases. Such protective effects are 
largely attributed to the antioxidant properties of MC. As MC extracts may be a potentially 
novel nutrient to delaying diabetic complications, it is of crucial importance to demonstrate 
that dietary supplementation of MC extract protects against the development of diabetic 
complications. In addition, all extracts have antioxidant properties and reduce oxidative 
stress. Moreover, MC extracts have pro-angiogenic action associated with phospho-ERK1/2 
over-expression. MC extracts have been shown to counter-act the anti-angiogenic effects of 
high concentration of AGEs. In addition, MC extracts activate ERK pathway via RAGE. 
Thus, consumption of MC may not only reduce hyperglycemia but also protect against 
diabetes-induced complications and deserves more attention. 
6.4 Future work 
 Wide investigations of the signalling pathways induced by MC extracts and charantin 
using protein micro-array. The wide investigation of the cytoplasmic proteins is to 
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increase our understanding of how the stimulated endothelial cells respond leading to 
angiogenesis.  
 Confirmation of in vitro angiogenic effects using in vivo assays such as CAM assay 
Confirmation of pro-angiogenic effects using in vivo angiogenesis assays such as murine 
in vivo Matrigel-based angiogenesis assay or ex ovo assay such as CAM assay. This study 
is mandatory to validate the pro-angiogenic effects of MC extracts and charantin. 
Additional information regarding the structure of the new blood vessels formed can be 
also examined. 
 Conduct an in vivo study using patient samples (clinical trial). Further clinical exploration 
in diabetic patients to validate these experimental findings and to develop MC extracts 
and charantin as potential wound repair therapy for impairment of the healing of acute 
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